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Stellingen 
i 
Fructo-oligosacchariden en transgalacto-oligosacchariden worden volledig gefermen-
teerd in het colon van gezonde mensen (dit proefschrift). 
2 
Fructo-oligosacchariden hebben geen gunstig effect op het glucose of lipidemetabolis-
me van niet-insuline afhankelijke diabeten (o.a. dit proefschrift). * 
3 
Studies naar het effect van niet-verteerbare oligosacchariden op de samenstelling van de 
darmflora zijn van weinig waarde als het effect niet wordt vergeleken met dat van een 
placebo behandeling (o.a. dit proefschrift). 
4 
Bij onderzoek naar de fysiologische effecten van niet-verteerbare oligosacchariden zijn 
mogelijke negatieve effecten op lange termijn tot dusver onderbelicht. 
5 
Het is onduidelijk of bij gezonde mensen een verlaging van de concentratie homocys-
teine in het plasma leidt tot een verlaging van het risico op hart- en vaatziekten (o.a. 
Kuller LH, Evans RW. Homocysteine, Vitamins, and Cardiovascular Disease. Circula-
tion 1998; 98:196-199). 
6 
Het effect van lijnen op het humeur ondermijnt het effect van lijnen op het lichaamsge-
wicht (o.a. Wells AS. Alterations in mood after changing to a low-fat diet. British Jour-
nal of Nutrition 1998; 79:23-30). 
7 
De status van de zeehond als ambassadeur van de waddenzee is gebaat bij een zekere 
mate van schaarsheid van zeehonden (Alles J. Selling Seals - Public Information and 
Education on the Ambassador of the Wadden Sea, Wadden Sea Newsletter 1996; 2:25-
30). 
Ver doorgevoerde bezuinigingen in de psychiatrie hebben geleid tot een toename van de 
emstige gevallen van burenoverlast (o.a. Riagg Oost-Veluwe. Evaluatieverslagproject 
hulpverlening in het kader van de OGGZ1997/1998). 
9 
Opvoeders doen er goed aan het voorlezen van hun kinderen tot een ritueel te maken 
(van de Wouw J. Rituelen, sfeerlezen en luisterspanning - Leesbevordering op de basis-
school. Bibliotheek & Samenleving 1991; 19:310-313). 
10 
Bij natuurbeschermers die zich verzetten tegen de plaatsing van windturbines speelt het 
NIMBY-effect ('Not In My Back Yard') een belangrijke rol. 
11 
In kringen van intellectuelen is het niet bevorderlijk voor je sociale status om te zeggen 
dat rv-kijken je hobby is. 
12 
Wie fecalien onderzoekt moet gemakkelijk over poep kunnen praten. 
Stellingen behorend bij het proefschrift 
Physiological effects of consumption offructo-oligosaccharides and transgalacto-
oligosaccharides 
Martine S. Alles. Wageningen, 18 december 1998. 
VoorJan en Annemiek 
Abstract 
Physiological effects of consumption of fructo-oligosaccharides and transgalacto-
oligosaccharides 
PhD thesis by Martine S. Alles, Division of Human Nutrition and Epidemiology, Wageningen 
Agricultural University, the Netherlands. 
Oligosaccharides naturally occur in many raw materials that are used for the manufacture of human 
foods. Plant oligosacccharides are often not digestible in the upper part of the gastrointestinal tract, 
but may be fermented in the colon by the intestinal microflora. These non-digestible 
oligosaccharides are generally considered dietary fiber. We studied the effects of two types of 
oligosaccharides, fructo-oligosaccharides and transgalacto-oligosaccharides, in humans using 
placebo controlled interventions. Special emphasis was put on measuring fermentation and on the 
effects on the composition of the intestinal microflora, putative colon cancer risk markers and 
glucose and lipid metabolism. We showed that healthy volunteers ferment fructo-oligosaccharides 
and transgalacto-oligosaccharides completely, as measured by the recovery of the oligomers in 
feces. The apparent fermentability of fructo-oligosaccharides by patients with an ileal pouch-anal 
anastomosis was 83%. Fermentation of both fructo-oligosaccharides and transgalacto-
oligosaccharides increased the excretion of breath hydrogen. When hydrogen is produced, most 
bacteria simultaneously produce short-chain fatty acids, but the fecal concentration of short-chain 
fatty acids after consumption of either fructo-oligosaccharides or transgalacto-oligosaccharides was 
not increased. Rapid absorption of the acids by the colonic mucosa probably occurred. We showed 
substrate specific changes of bacterial glycosidase activity in fecal water after dietary intervention 
with non-digestible oligosaccharides and conclude that the glycolytic activity of the intestinal 
bacteria might be a useful biomarker of the colonic metabolic activity. We found no effects of 
transgalacto-oligosaccharides on the composition of the intestinal microflora of healthy volunteers, 
when tested in a controlled feeding trial against a placebo treatment. There were no effects of 
fructo-oligosaccharides and transgalacto-oligosaccharides on stool weight or on the fecal 
concentration of butyrate, nor effects of transgalacto-oligosaccharides on fecal bile acid profiles or 
on the concentration of fecal toxic protein fermentation products. We showed that fructo-
oligosaccharides do not favorably affect fasting glycaemia or serum lipids in non-insulin dependent 
diabetic patients that are under strict medical control for their diabetes. Although fructo-
oligosaccharides and transgalacto-oligosaccharides are completely fermented, we were unable to 
find any evidence that they beneficially affect putative colon cancer risk markers, the composition 
of the intestinal microflora or glucose and lipid metabolism. It remains possible that they have 
effects in other study-populations, when tested against another background diet or when combined 
with other fermentable substrates. 
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General introduction 
Chapter 1 
Background 
Oligosaccharides are naturally present carbohydrates in many raw materials that are used for the 
manufacture of human foods. The number of possible oligosaccharide structures is extremely large 
as each monosaccharide has several free hydroxyl groups that can form a link to another 
monosaccharide. Simple oligosaccharides, such as the a-galacto-oligosaccharides and B-fructo-
oligosaccharides that are present in crop plants, are energy stores in plant seeds and mobilized 
during germination. Plants also contain more complex oligosaccharides, which may be covalently 
linked to proteins in glycoproteins and to lipids as glycolipids. Their function is largely unknown 
(Alberts et al, 1994). Oligosaccharides can also be formed during food processes such as beer 
brewing (Lehtonen & Hurme, 1994), wine production (Castino, 1972), bread baking (Rodionova et 
al, 1995) and in the processing of fruits for fruit juices (Schols, 1995). 
Many of the plant oligosaccharides are not digestible in the upper part of the gastrointestinal 
tract. These non-digestible oligosaccharides are considered dietary fiber by most professionals in 
the field (Lee & Prosky, 1995), however, with the official AOAC analysis of total dietary fiber, 
oligosaccharides are not measured and therefore often not mentioned in food tables (Deutsch, 1997). 
The mean intake of dietary fiber without oligosaccharides, based on the official methods of analysis, 
is 23 g per day in the Netherlands (Anonymous, 1996; Anonymous, 19936). Little is known about 
the non-digestible oligosaccharide content of foods and the mean intake of non-digestible 
oligosaccharides. Van Loo et al (1995) estimated the average daily intake of plant 6(2-1 )-fructans, 
inulin and fructo-oligosaccharides to be 1-4 g per day in the North American population. The main 
sources were wheat and onions. Obviously, oligosaccharides significantly contribute to the dietary 
fiber fraction in our diet. 
Oligosaccharides can be made industrially by extraction from foods, transglycosylation 
reactions or by hydrolysis of polysaccharides. When extracted from foods, they are obtained in their 
natural form. Enzymatically produced oligosaccharides are not always naturally occurring food 
components. 
Interest in the specific health effects of non-digestible oligosaccharides originates from 
Japan, where oligosaccharides are extracted on a large scale from soybean whey and used as 
additive in health foods (Fujii & Komoto, 1991). More than ten years ago, Japanese studies already 
pointed to possible favorable effects of non-digestible oligosaccharides on colonic health (Tanaka et 
al, 1983; Minami et al, 1985; Mitsuoka et al, 1987; Masai et al, 1987; Kohmoto et al, 1988). 
However, most of these Japanese studies had no strict study design and were restricted to elderly 
subjects. The recent commercialization of non-digestible oligosaccharides as functional food 
ingredients has triggered much research in Western countries. Non-digestible oligosaccharides 
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might alter both the composition and the activity of the colonic microflora, and may -via 
endproducts of fermentation- have favorable effects on colon cancer risk and on glucose- and 
lipidmetabolism. 
Rationale of the thesis and project team 
In our studies, several hypotheses concerning effects of fructo-oligosaccharides and transgalacto-
oligosaccharides in humans with Western dietary patterns were tested using placebo controlled 
interventions. Fructo-oligosaccharides naturally occur in various edible plants, such as onions and 
bananas, and are defined as those oligosaccharides belonging to the fructan family (Van Loo et al, 
1995). Transgalacto-oligosaccharides are 13-galacto-oligosaccharides that are produced from lactose 
by enzymatic transgalactosylation. Similar components and fi-galacto-oligosaccharides with a more 
complex structure are present in human breast milk. Special emphasis was put on measuring 
fermentation, on the composition of the intestinal microflora, on colon cancer risk markers and on 
glucose- and lipidmetabolism. Table 1 summarizes the treatment, design and key-variables in the 
studies that are described in Chapters 2-6. 
In Chapters 2, 4 and 5, we studied effects of oligosaccharides in healthy volunteers. In Chapter 3, a 
group of patients with an ileal pouch-anal anastomosis was studied. In these patients, the colon is 
removed and part of the distal ileum is constructed into an anal reservoir which takes over part of 
the function of the colon. In Chapter 6 we studied the effects of fructo-oligosaccharides on glucose 
and lipidmetabolism in non-insulin dependent diabetic patients. Finally, in Chapter 7 the main 
findings are presented, and methodological issues and possibilities for further research are 
discussed. 
The thesis was part of a multi-disciplinary research program at the Wageningen Agricultural 
University on the role of non-digestible oligosaccharides in food and feed. Four departments were 
involved in the project: Human Nutrition and Epidemiology, Animal Nutrition, Food Microbiology 
and Food Chemistry. 
In the following six paragraphs, the rational of this thesis will be explained in more detail. 
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General introduction 
Structure of fructo-oligosaccharides and transgalacto-oligosaccharides 
We studied the effects of two types of oligosaccharides; fructo-oligosaccharides (Raftilose P95®, 
ORAFTI, Tienen, Belgium) and transgalacto-oligosaccharides (Elix'or®, Borculo Whey Products, 
Borculo, Netherlands). These products were chosen for practical reasons as they had the legal status 
of food ingredients and were obtainable in large enough quantities for human trials. 
The oligosaccharides from Raftilose® are made from inulin which is extracted from chicory 
roots. The degree of polymerization of the fructo-oligosaccharides present in Raftilose® ranges from 
2 to 7. The oligomers consist of fructose-units with or without a terminal glucose-unit. Linkages 
between the monosaccharide units are 13-2,1. The general structure is given in figure 1. 
CH,OH 
n=l-6 
H-CH OH 
P. n=l-6 
1 
Figure 1. Fructo-oligosaccharides (Raftilose P95®, ORAFTI, Tienen, Belgium) with (left) or 
without (right) endstanding glucose molecule. 
Elix'or® is produced from lactose by enzymatic transgalactosylation, using a B-galactosidase. It has 
a variety of oligomers consisting of glucose and galactose-units with mainly 6-1,4, but also B-1,2, B-
1,3 and 13-1,6 linkages (Yanahira et al, 1995). The degree of polymerization of the transgalacto-
oligosaccharides is 2 to 7. The structure is given in figure 2. 
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<P40H CH, OH 
-o 1—o 
CH OH 
O 
B-D-Galp-(l-4)-fi-D-Glcp B-D-Gal/7-(l-4)-B-D-Gak>(l-4)-B-D-Glc/> 
CHjOH CHjOH 
- O 1——O 
CH.OH CH OH 
-O J-i-0 
6-D-Gal/)-(l-4)-8-D-Galp-(l-4)-B-D-Gal/7-(l-4)-B-D-Glc/) 
Figure 2. Examples of transgalacto-oligosaccharides made from lactose (upper left) (Elix'or®, 
Borculo Whey Products, Borculo, Netherlands). 
Digestion and absorption 
Human alimentary enzymes are not equipped with B-fructosidase or B-galactosidase activity. The 
enzyme lactase is an exception and only capable of degrading lactose. As a consequence fructo- and 
transgalacto-oligomers are able to survive partly the passage through the upper part of the gastro-
intestinal tract (stomach and small bowel). 
Digestion of fructo-oligosaccharides has been studied in vitro (Oku et al, 1984) and in vivo 
(Tokunaga et al, 1989; Bach Knudsen & Hessov, 1995; Molis et al, 1996). Three human trials were 
done to quantify the passage of fructo-oligosaccharides into the colon, two in ileostomy patients 
(Bach Knudsen & Hessov, 1995; Ellegard et al, 1997) and one in healthy volunteers, using an 
intubation technique (Molis et al, 1996). Both studies showed small losses (<13%) of the oligomers 
in the upper part of the gastrointestinal tract, probably due to hydrolysis in the stomach and 
microbial degradation in the small intestine. Hydrolysis by either pancreatic or intestinal enzymes 
did not occur. 
14 
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Digestibility of transgalacto-oligosaccharides was studied in vitro showing that they are acid stable 
(unpublished results) and not hydrolyzed by lactase (Burvall et al, 1980). There are no studies on 
the small intestinal degradation of transgalacto-oligosaccharides in vivo. 
A few studies investigated the possible absorption of the intact fructo-oligomers by the 
intestinal wall. Small traces of fructo-oligosaccharides were measured in some of the urine-samples 
of volunteers on fructo-oligosaccharide-rich diets (Rumessen et al, 1990; Molis et al, 1996). In 
Chapter 2 we measured fructo-oligosaccharides in urine. 
Fermentation 
Substances that escape digestion by endogenous enzymes in the upper part of the gastrointestinal 
tract, may serve as substrates for the colonic microflora, which possesses a large enzymatic 
potential (Szylit & Andrieux, 1993). Colonic fermentation is the anaerobic process in which 
carbohydrates and proteins are metabolized by the intestinal microflora. Fermentation of 
carbohydrates will increase the production of gases, short-chain fatty acids such as acetate, butyrate 
and propionate and sometimes of lactate or ethanol. Protein fermentation increases the production of 
the branched chain fatty acids iso-butyrate and iso-valerate, and of phenolic compounds and 
ammonia. The colonic fermentative activity is regulated by the amount and type of substrate that 
enters the colon, such as endogenous compounds and undigested food components. It seems likely 
that the composition of the diet is of influence on the activity of the intestinal microflora 
(Cummings & MacFarlane, 1991). 
The apparent fermentability of specific oligosaccharides can be measured in 
supplementation trials by determining the fecal excretion of the undigested and unfermented 
substance. In Chapters 2-4 we studied the excretion of oligosaccharides in feces. Also, the 
endproducts of fermentation can be measured, such as hydrogen in breath or short-chain fatty acids 
in feces. To study the metabolic activity of the intestinal microflora, we measured different 
endproducts of fermentation after consumption of fructo-oligosaccharides {Chapter 2) and 
transgalacto-oligosaccharides (Chapter 4) in healthy humans and pouch patients (Chapter 3). In 
patients with ileal pouches (Chapter 3), we expected to find more profound effects on the fecal 
concentration of short-chain fatty acids. Fermentation metabolites are efficiently absorbed by the 
colon mucosa, but in pouch patients, the frequency of defecation is high and as a result, the time 
available for absorption is limited. We therefore hypothesized to find a lower absolute uptake of 
short-chain fatty acids by the pouch mucosal wall. The activity of bacterial glycolytic enzymes that 
are involved in the fermentation of oligosaccharides was studied in Chapter 5. 
15 
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Composition of the intestinal microflora 
The microbial component of feces is estimated at 55% of the solids (Stephen & Cummings, 1980). 
Many different species of bacteria occur in the human large bowel. The majority is anaerobic, with 
the predominant genus being Bacteroides. Other important anaerobic species are bifidobacteria, 
lactobacilli and Clostridia. The composition of the colonic microflora was always thought to be very 
stable over long periods of life (Simon & Gorbach, 1984), but some of the early Japanese studies 
showed that non-digestible oligosaccharides might induce beneficial changes (Tanaka et al, 1983; 
Minami et al, 1985; Mitsuoka et al, 1987; Masai et al, 1987; Kohmoto et al, 1988). Especially 
bifidobacteria were shown to be selectively stimulated by specific oligosaccharides. Bifidobacteria 
may comprise up to one quarter of the gut flora of normal healthy adults (Modler et al, 1990). They 
have a role in controlling the pH of the large intestine, through the production of lactic and acetic 
acid. A low pH might restrict the growth of many potential pathogens and putrefactive bacteria 
(Gibson & Wang, 1994; Modler et al, 1990) and might both depress the formation of secondary 
from primary bile acids and enhance the precipitation of bile acids (Hofmann & Mysels, 1992; 
Munster et al, 1994b; Nagengast et al, 19886; Rafter et al, 1986). Cellular components of 
bifidobacteria may act as immunomodulators (Mitsuoka, 1990; Gibson & Roberfroid, 19956). 
Some recent studies confirmed the early reported effects of non-digestible oligosaccharides 
on the composition of the intestinal microflora (Ito et al, 1990; Buddington et al, 1996; Bouhnik et 
al, 1997; Bouhnik et al, 19966; Gibson et al, 1995a). In most of these studies, a linear study design 
was used and possible time and placebo effects were thus neglected. In Chapter 4, we compared the 
effects of transgalacto-oligosaccharides on the composition of the intestinal microflora with the 
effects of a placebo. 
Colon cancer risk markers 
Colorectal cancer is one of the most common malignancies in the Netherlands, as in most other 
Westernized countries (Netherlands Cancer Registry, 1990). Dietary patterns are considered to 
contribute to the etiology of sporadic (rather than inherited) colon cancer and especially dietary 
fiber might play a protective role here (Trock et al, 1990; Dwyer, 1993; Howe et al, 1992). Colon 
cancer risk may be modified by several fermentation related mechanisms (figure 3). 
A low stool weight, as seen in many Westernized populations (80-120 g/d) is associated 
with increased colon cancer risk (Cummings et al, 1992). Fermentable carbohydrates are thought to 
increase fecal biomass (Cummings et al, 1992; Cummings & MacFarlane, 1991; Stephen & 
16 
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Cummings, 1980; Gibson et al, 1995a). The effect of daily consumption of non-digestible 
oligosaccharides on fecal weight is reported in Chapter 2, 3 and 4. 
Colonic fermentation of non-digestible oligosaccharides may lead to an increase in the fecal 
concentration of butyrate (Younes et al, 1995; Roland et al, 1995; Campbell et al, 19976). Butyrate 
is a putative protective factor towards colon cancer (Garnet et al, 1992; Scheppach et al, 1995; 
Csordas, 1996). It is a major fuel for the colonic mucosa and may inhibit cell proliferation and 
stimulate cell differentiation. The fecal concentration of short-chain fatty acids, including butyrate, 
was studied after consumption of fructo-oligosaccharides {Chapter 2 and 3) and transgalacto-
oligosaccharides (Chapter 4). 
Daily, about 5-10% of the bile acids that are used for the solubilization of lipids in the small 
intestine enter the colon. The primary bile acids (mainly cholate and chenodeoxycholate, conjugated 
with either glycine or taurine) are deconjugated and dehydroxylated by the colonic flora into the 
secondary bile acids (deoxycholate and lithocholate), which might have promoting effects on 
colonic carcinogenesis (Lapre & Meer, 1992; Bruce, 1987; Munster & Nagengast, 1993). Non-
digestible oligosaccharides might lower the amount of secondary bile acids in fecal water (Rafter et 
al, 1986; Hofmann & Mysels, 1992; Reddy et al, 1992; Nagengast et al, 19886; Munster et al, 
19946; Christl et al, 1997). In Chapter 4, the effect of transgalacto-oligosaccharides on the profile 
of bile acids in fecal water is examined. 
Endproducts of the bacterial degradation of proteins, such as ammonia, indoles and skatoles, 
might have adverse effects and are potentially associated with colonic cancer (Birkett et al, 1996; 
Clausen & Mortensen, 1992a; Clinton et al, 1988; Bone et al, 1976). Supplying the colon with 
fermentable carbohydrates might lower the concentration of the protein degradation products. In 
Chapter 3 and 4 we examined the effects of fructo-oligosaccharides and transgalacto-
oligosaccharides on the fecal concentrations of various protein fermentation products. 
Some of the bacterial enzymes with glycolytic activity might have adverse effects in the 
colon. (3-glucuronidase is involved in the hydrolysis of glucuronide conjugates in the gut, which 
leads to the generation of toxic and carcinogenic metabolites (Rowland, 1988; Mallett & Rowland, 
1987). The hydrolytic activity of J3-glucosidase is responsible for the generation of mutagenic 
aglycones (Mallett & Rowland, 1987). Several studies show that dietary fiber may lower these fecal 
bacterial enzymes (Reddy et al, 1992; Buddington et al, 1996; Mallett & Rowland, 1987). In 
Chapter 5, we studied the bacterial glycosidase activity of fructo-oligosaccharides and transgalacto-
oligosaccharides. 
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General introduction 
Glucose- and lipid metabolism 
The short-chain fatty acids that are produced during fermentation of non-digestible oligosaccharides 
are thought to be readily absorbed by the colonic mucosa (Pomare et al, 1985; Cummings et al, 
19876; Rombeau & Kripke, 1990). It is known that butyrate serves as a fuel for the mucosa, 
whereas acetate and propionate enter the portal blood and may influence systemic carbohydrate and 
lipid metabolism (Cummings et al, 1987ft). One study with non-insulin dependent diabetic patients 
showed a decrease in both fasting blood glucose and serum lipids after consumption of fructo-
oligosaccharides (Yamashita et al, 1984). Several rat experiments confirmed these results (Kok et 
al, 1996; Fiordaliso et al, 1995; Levrat et al, 1994; Delzenne et al, 1993), but two studies with 
healthy volunteers failed to show an effect of fructo-oligosaccharides on serum lipids or glucose 
metabolism (Luo et al, 1996; Pedersen et al, 1997). In Chapter 6, we investigated the effects of 
fructo-oligosaccharides in non-insulin dependent diabetic patients on serum acetate concentrations, 
fasting glycaemia and serum lipids. 
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Fate of fructo-oligosaccharides in the human intestine 
Martine S. Alles, Joseph G.A.J. Hautvast, Fokko M. Nagengast, Ralf Hartemink, Katrien M.J. Van 
Laere, Jan B.M.J. Jansen. British Journal of Nutrition 1996; 76:211-221. 
Abstract 
There is a need for studies on colonic fermentation in order to learn more about health and diseases 
of the colon. The aim of the present study was to evaluate the fate of two different doses of fructo-
oligosaccharides (5 and 15 g/d) v. glucose in the intestine of healthy men. Twenty-four volunteers 
participated in a 5-week study. The study was a completely balanced multiple crossover trial using 
an orthogonal Latin-square design for three periods, with supplement periods of 7 d and two 7 d 
wash-out periods. Breath samples and fecal samples were collected. There was a clear gaseous 
response to the consumption of fructo-oligosaccharides. The highest dose significantly increased 24 
h integrated excretion of breath hydrogen (P < 0.05). Breath hydrogen excretion after ingestion of 5 
g fructo-oligosaccharides was higher than control, but did not reach significance. No effects on the 
total concentration of short-chain fatty acids in feces were observed, no modification of the molar 
proportions of the various short-chain fatty acids was observed. The fecal pH did not change. No 
changes in fecal weight were observed. No fructo-oligosaccharides were recovered in feces. We 
conclude that fructo-oligosaccharides added to the diet of young Western subjects are fully 
metabolized in the large intestine. The level of fermentation seems to be dose dependent. 
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Introduction 
Studies on the effects of non-digestible oligosaccharides in elderly Japanese subjects suggest that 
dietary supplementation with fructo- or galacto-oligosaccharides is beneficial to the large intestine 
(Masai et al, 1987; Hidaka et al, 1986; Mitsuoka et al, 1987; Ito et al, 1990; Hayakawa et al, 1990). 
The studies show a higher activity of the colonic microflora in response to the consumption of 
oligosaccharides, as demonstrated by increased fermentation. During carbohydrate fermentation, 
gases and short-chain fatty acids are formed (Cummings et al, 1987a; Wang & Gibson, 1993). The 
production of short-chain fatty acids and the subsequent drop in colonic pH might protect against 
colonic cancer (Koo & Rao, 1991; Munster et al, 19946). It is also suggested that oligosaccharides 
selectively stimulate bifidobacterial growth and thereby change the microfloral composition. Since 
bifidobacteria are considered to be beneficial genera, they may contribute to the establishment of a 
more healthy colonic environment (Mitsuoka, 1990; Modler et al, 1990; Gibson et al, 1995a). 
However, because the Japanese studies often lacked a strict study design or focused primary 
on elderly people, we feel that they do not elucidate the metabolic fate of oligosaccharides in the 
large intestine. Also, observations made in Japan might not be applicable to populations with 
Western dietary patterns. Only a few studies have been performed within Western populations so far 
and they have not investigated to what degree the oligosaccharides are fermentable (Stone-Dorshow 
& Levitt, 1987; Rumessen et al, 1990; Gibson et al, 1995a). Thus, we need more information to 
evaluate the fermentation process of oligosaccharides. 
The purpose of the present study was to examine the fate of fructo-oligosaccharides in the 
human intestine by studying several aspects of colonic fermentation in healthy young adults 
consuming a Western diet. The excretions of unfermented fructo-oligosaccharides and short-chain 
fatty acids in the feces, and hydrogen in the breath were measured. 
Methods 
Subjects and experimental design 
Twenty-four healthy men aged 19-28 years volunteered to participate in the study. Women were 
excluded because of the possible influence of the menstrual cycle on fermentation (McBurney, 
1991). All subjects had normal body weight (BMI 21.7 (SD 1.9) kg/m2), had no history of diabetes 
or gastrointestinal disease, and had not recently been treated with antibiotics or laxatives. They were 
not under any medication and blood screening tests were normal. None of the volunteers smoked. 
Four volunteers were vegetarians, none of the volunteers used a special diet. 
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To avoid excess hydrogen being channeled into methane production, subjects chosen were non-
methane producers. Three breath samples were collected on separate days, from each volunteer, 
before the study. Volunteers were classified as methane excreters, when in one or more of the 
samples the methane concentration exceeded 3 ppm above ambient air (Rumessen, 1992a; 
Nagengast et al, 1988a). Characteristics of the study population are given in Table 1. 
Table 1. 
Characteristics and dietary intake of the subjects 
Mean SD 
Age (y) 22l H 
Weight (kg) 74.0 8.9 
Height (m) 1.85 0.1 
BMI(kg/m2) 21.7 1.9 
Energy intake (MJ) 13.7 3.6 
Carbohydrate intake (%EI) 50.4 7.4 
Fat intake (%EI) 34.2 6.2 
Protein intake (%EI) 12.1 1.8 
Dietary fiber (g) 39.7 11.9 
Mean values for twenty-four male subjects and standard deviations between subjects (SD). 
BMI, body mass index; EI, energy intake. 
The study was a completely balanced multiple crossover trial using an orthogonal Latin-square 
design for three treatments, with supplement periods of 7 d and two 7 d wash-out periods between 
treatments. The volunteers consumed three different supplements in random order. At the end of 
each supplement period feces, breath and urine samples were collected. 
All subjects gave their informed written consent before participating. The study protocol was 
approved by the Ethical Committee of the Department of Human Nutrition, Wageningen 
Agricultural University. 
Supplements and food intake 
Diet composition was calculated in every supplement period from 2 d estimated records, using the 
1986-1987 release of The Netherlands nutrient data bank (Anonymous, 1987). Volunteers were 
asked to refrain from eating any fermented dairy products during the study. 
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The supplements consisted of fructo-oligosaccharides (Raftilose® P95; ORAFTI, Tienen, Belgium) 
and/or glucose (Cerestar Pur 01934; Cerestar Benelux BV, Sas van Gent, The Netherlands) in the 
following quantities: control, 0 g fructo-oligosaccharide+4.1 g glucose; SF5, 5 g fructo-
oligosaccharide+2.7 g glucose; SF15,15 g fructo-oligosaccharide+O g glucose. They were dissolved 
in water and were of equal osmolality. 
Supplements were consumed in split dose together with breakfast and dinner. To estimate 
stool recovery, thirty barium impregnated rings were swallowed daily together with the supplements 
and were counted afterwards in the fecal samples. A small dose (240 umol) of lithiumchloride 
(Merck, Darmstadt, Germany) was added to each supplement. To check for compliance, the 
recovery of lithium in 24 h urine was measured on the last 2 d of every supplement period 
(Sanchez-Castillo et al, 1987; Leclercq et al, 1990; Houwelingen et al, 1987). 
Data collection 
Body weight was measured on the first day of every supplement week, using electronic scales with 
a digital read-out to an accuracy of 0.05 kg (ED60-T; Berkel, Rotterdam, The Netherlands). 
During the whole study period, volunteers kept a diary. They recorded time of supplement 
consumption, time of defecation, possible diseases or medication and deviations in eating, drinking 
or living behavior. Stool form was rated for all stools on a 5-point Likert scale which was based on 
the scale by Heaton et al (Heaton et al, 1992) (watery; soft, pudding-like; soft, snake-like; dry, 
cylindric; dry, hard pellets). Gastrointestinal complaints concerning flatulence, bloating, abdominal 
pains or cramps, eructations, nausea, vomiting and stomach pains or cramps were rated on a 4-point 
Likert scale (none; mild; moderate; severe). 
Volunteers came to the Department of Human Nutrition twice at the end of each supplement 
period to defecate. Within 15 min after defecation the feces were weighed and immediately deep-
frozen on dry ice to stop fermentation, then stored at -20 °C. On the last day of each supplement 
period, end-expiratory breath samples were taken at the Department of Human Nutrition at 4 h 
intervals from 08.00 hours (fasted) until 20.00 hours and again at 08.00 hours (fasted) the next 
morning. Urine (24 h) was collected on the last 2 d of every supplement period and 5 ml glacial 
acetic acid was added to all urine bottles before collection as a preserving agent. 
Analytical procedures 
The 24 h urine samples were pooled when both collections were complete. Lithium was measured 
as described previously (Leclercq et al, 1990) using an atomic absorption spectrophotometer (Type 
2380, Perkin-Elmer, Norwalk, USA). Calibration was done with a standard concentration of 100 
umol/1 and with water as a blank. 
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End-expiratory breath samples and ambient air samples were collected in plastic 60 mL syringes 
(Plastipak; Becton Dickinson, Dublin, Ireland). Methane was measured in end-expiratory breath 
samples, using gas chromatography (Chrompack 438 AS; Hewlett Packard 427, Middelburg, The 
Netherlands). Calibration was done (daily) with 5 ppm and 29 ppm methane-in-nitrogen gases 
(Intermar BV, Breda, The Netherlands). Within 2 h after collection the hydrogen concentration was 
measured using a standard electrochemical cell (Exhaled Hydrogen Monitor; Gas Measurement 
Instruments Ltd., Renfrew, Scotland). The cell was calibrated with a standard gas of 100 ppm 
hydrogen in air (Intermar BV) 
All fecal samples were X-rayed before analysis to determine the number of barium rings 
(Philips Optimus M200, Eindhoven, The Netherlands). Dry weight of the feces was estimated by 
drying a portion for 4 d at 80 °C (Heraeus E45, Hanau, Germany). For the preparation of the 
aqueous fraction of stool the samples were thawed overnight at 4 °C. The two samples from each 
week were homogenized in a bowl and mixer. A portion was ultracentrifuged at 26.000 g for 90 min 
at 4 °C (MSE, Scientific Instruments, Crawley, United Kingdom). Fecal water was carefully 
removed and stored at -20 °C until analysis. The pH was measured in both fecal homogenate and 
fecal water with a digital pH meter (CD 620; WPA Ltd, Cambridge, United Kingdom). 
Short-chain fatty acids were measured in fecal water as described by van Munster et al 
(19946), using a Packard gas chromatograph (column: 10% SP1200 / 1% H3P04 on 80/100 
Chromosorb WAW, Hewlett Packard, Middelburg, The Netherlands). The fructo-oligosaccharides 
present in feces were determined in 0.25 g freeze-dried feces. This was suspended in 5 ml water, 
vortex-mixed and boiled for 10 min. The suspension was centrifuged at 4500 rev./min for 25 min. 
The supernatant fraction was analyzed by high-performance anion-exchange chromatography 
(Dionex BV, Breda, The Netherlands). The system consisted of a gradient pump and programmable 
pulsed electrochemical detector. Separations were performed using a Carbopack PA-100 analytical 
column (4*250 mm, Dionex BV, Breda, The Netherlands). The chromatographic mobile phase 
consisted of 0.1 M NaOH (A) and 1 M Na-acetate containing 0.1 M NaOH (B). A linear gradient 
was used from 100% A to 70% A plus 30% B in 25 min with a flow of 1 ml/min. Samples were 
compared with spiked samples, containing three oligomers from Raftilose P95® (GF2, GF3 and 
GF4). The same HPLC method was used in undiluted urine samples for the detection of fructo-
oligosaccharides in urine. 
Data analysis and statistics 
The 24 h integrated breath-hydrogen excretion was estimated by calculating geometrically the area 
under the curve of concentration v. time (Wolever & Jenkins, 1986). Results are expressed as means 
and standard errors, unless stated otherwise. The distributions of the differences between the three 
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treatments were checked for normality by visual inspection of the normal probability plots. The 
significance of the differences between the three supplements in each subject was assessed by 
analysis of variance without interactions (General Linear Models procedure). Because of a small 
number of missing values in the data-set, leading to non-orthogonality of the model, the variable 
'period' was added to the model. 'Period' did not contribute to the significance of the model, nor 
did it change any of the conclusions. Therefore the model used in the final analysis contained only 
'subject' and 'treatment'. In cases of a significant difference (P < 0.05) between treatments, group 
means were tested with the Tukey or Scheffe tests. 
An exception to the given method of analysis was made for the breath hydrogen data. 
Because of excessive numbers of missing values, we used the least-square means statement to 
estimate mean values for each supplement and to evaluate differences between treatments in a 
model including 'subject', 'period' and 'treatment'. This analysis accounts for unequal cell sizes; 
least-square means are estimators of the marginal means that would be expected had the design been 
balanced. The statistical analyses package SAS, version 6.09 (SAS Institute, Inc., Cary, NC) was 
used to perform the statistical analyses. 
Results 
Supplements and food intake 
None of the volunteers experienced great difficulties with the consumption of the supplements. All 
volunteers completed the study successfully. The recovery of lithium in urine was significantly 
lower (P < 0.05) after consumption of SF15 (82%) than after consumption of control (90%). The 
results of the 2 d food records obtained during each supplement period revealed no changes in the 
average daily intakes of energy, protein, fat, carbohydrates or dietary fiber. Mean values of dietary 
intakes from 6 d food records are given in Table 1. 
Diaries 
The information from the diaries is presented in Table 2. Gastrointestinal complaints concerning 
flatulence were significantly higher (P < 0.001) during consumption of SF15 compared with the 
control supplement. Although flatulence did not rise significantly during SF5, there was a visible 
trend towards a higher level. All other symptom scores were low and equal for the three supple-
ments. 
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Chapter 2 
There were no differences in recorded stool form between control and SF5. During SF15, stool form 
was rated somewhat lower and was more watery. This decrease, however, was not significant. No 
differences were found in frequency of defecation between the supplements. 
Colonic fermentation 
Because of a technical defect of the exhaled hydrogen monitor in the last week of the experiment, 
we only obtained sixteen observations of hydrogen excretion (instead of twenty-four) in each 
supplement group. Figure 1 shows the mean breath hydrogen curve for each supplementation. When 
comparing the separate hydrogen levels at different times we observed a significantly higher 
response (P < 0.01) at 12.00 hours for SF15. 
£ P. a 
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o> 
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Time of day (hours) 
04:00 08:00 
Figure 1. Least-square means (LS Means) of breath hydrogen concentration (ppm) at regular time 
intervals on the seventh day of supplementation with 0 (•), 5 (•) or 15 g (A) of fructo-
oligosaccharides. LS Means are based on sixteen observations for each plotted point. (B) time of 
supplement ingestion. * P < 0.01 in comparison with control. 
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Chapter 2 
Table 3 summarizes the fermentation data. When expressing the hydrogen excretion as the area 
under the hydrogen-time curve (AUC), there was an increase in AUC from control (682 ppm.h) to 
SF5 (714 ppm.h; P=0.1S, compared with control) to SF15 (986 ppm.h; P=0.02, compared with 
control). 
No changes in fecal weight were observed. The observed difference in wet weight between 
control and SF15 (or SF5) did not vary in any systematic way over the range of measurements. 
There was no significant correlation between differences in wet weight in response to 
supplementation and average values of wet weight (for SF5: r -0.03; P = 0.89, for SF15: r -0.26; P = 
0.26). Four observations were excluded from the analysis of wet weight because volunteers had 
forgotten to swallow all barium rings in that week, making it impossible to estimate daily producti-
ons. 
c o 
•3 
O H 
Retention time (min) 
Figure 2. Typical HPLC patterns for one of the volunteers. Samples were (A) Raftilose P95®, (B) 
fecal sample after supplementation with fructo-oligosaccharides, spiked with three oligomers from 
Raftilose P95® (arrows), (C) the same fecal sample, unspiked. 
Fecal dry weight, expressed as a percentage of wet weight, did not change in response to the 
supplementation. No traces of the fructo-oligosaccharides that were provided in the supplement 
were recovered in feces of any of the samples. Figure 2 gives an example of a typical HPLC elution 
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pattern for a fecal sample from one of the volunteers during SF15. Response A is Raftilose P95®, 
response B is the sample spiked with the Raftilose P95® oligomers GF2, GF3 and GF4, response C 
is the unspiked sample. In addition to fecal analyses, we also analyzed urine samples for fructo-
oligosaccharides. In none of the samples were any fructo-oligosaccharides detected. 
Concentrations of short-chain fatty acids were measured in fecal water. No accumulation of 
these fermentation products was observed. As shown in Figure 3, the relative contribution of 
different short-chain fatty acids did not change. The pH-values of fecal water and homogenate were 
not altered in response to the different supplements. Because there were three cases in which the 
amount of extractable fecal water was negligible, fecal short-chain fatty acids and pH of fecal water 
could not be measured for these observations. There was a significant negative correlation between 
the pH of fecal water and the total amount of short-chain fatty acids (r -0.57, P < 0.0001) as measu-
red in fecal water. 
Acetate 
Propionate 
Butyrate 
Valerate 
Total SCFA 
"\ 
\ 1 h-
1 
1 1 1 1 
^ ^ ^ 1 
1 1 1 
20 40 60 80 100 120 
Short-chain fatty acids in fecal water 
140 160 
Figure 3. Mean concentration of short-chain fatty acids (SCFA) as measured in fecal water obtained 
from two pooled stools, after 5-7 d of dietary supplementation with 0 (white), five (black) or 15 g 
(grey) fructo-oligosaccharides. 
Discussion 
This study shows that fructo-oligosaccharides are completely fermented in the large intestine. 
Complete malabsorption in the small intestine was confirmed, since no fructo-oligosaccharides were 
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detected in any of the urine samples, and it has been shown that fructo-oligosaccharides are not 
metabolized by human digestive enzymes in the small intestine (Nilsson & Bjorck, 1988; Oku et al, 
1984; Tokunaga et al, 1989) and thus reach the large intestine. We demonstrated fermentation 
positively through the observed increase of breath hydrogen excretion. This fermentation was 
complete, since no fructo-oligosaccharides were excreted in feces during the last two days of each 
supplementation period. The present study is the first to show the complete fermentation of fructo-
oligosaccharides in an in vivo experiment. 
The increase of hydrogen excretion during fermentation of fructo-oligosaccharides has also 
been observed by other investigators (Stone-Dorshow & Levitt, 1987; Rumessen et al, 1990; 
Gibson et al, 1995a). The level of breath hydrogen excretion seems to be dose dependent. During 
SF5 the excretion was higher than during the control period, although it did not reach significance. 
At the SF15 level, the excretion of hydrogen was significantly higher than during the control 
treatment. This dose effect was also observed by Rumessen et al (1990) using fructans, which are 
longer-chain oligomers. It is unlikely that the effect on hydrogen excretion during SF5 was missed 
because of a rapid fermentation and short-lived increases of breath hydrogen. The hydrogen 
response to fructo-oligosaccharides might be rapid, but the concentration is shown to be elevated for 
at least 6 h after supplementation (Stone-Dorshow & Levitt, 1987). A more likely explanation for 
the very small difference between control and SF5 is that the effect was masked by the meal-related 
hydrogen response. In the present study, it was impossible to test for linearity, since we only tested 
three doses of fructo-oligosaccharides. However, in a study by Rumessen et al (1990) the excretion 
of hydrogen in breath increased linearly with the consumption of up to 20 g lactulose. 
We did not find any increase in short-chain fatty acid concentration in feces after 
supplementation with fructo-oligosaccharides and, consequently, no changes in the average pH-
values of fecal water. Short-chain fatty acids are mainly produced in the proximal colon where the 
amount of available substrates is highest (MacFarlane et al, 1992). Rapid absorption by the colonic 
mucosa leads to a lower concentration in the feces (Hoverstad et al, 1982; Cummings et al, 1987a). 
This is probably the reason that we did not find the expected changes in short-chain fatty acids or 
pH. Our results were in accordance with the recent findings of Gibson et al (1995a), who published 
a study investigating the effects of fructo-oligosaccharides on large-bowel microflora and colonic 
function in a controlled feeding trial (n 8). They did not observe any major differences in fecal 
short-chain fatty acid concentration between supplementation with 15 g fructo-oligosaccharides or 
sucrose. In an experiment by Mitsuoka et al (1987), the effects of fructo-oligosaccharides on 
intestinal microflora and fecal pH were evaluated. Elderly patients (n 23) participated in a 3-week 
experiment. They consumed 8 g of fructo-oligosaccharides/d for 2 weeks. Fecal collection took 
place before, during and after administration. A mean decrease of fecal pH (by 0.3 units) was 
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observed, but no information was given on variations or levels of significance. No control treatment 
was used. 
In the present study, supplementation with fructo-oligosaccharides, even at the SF15 level, 
did not cause changes in stool form, wet or dry weight of feces or frequency of defecation. Our 
findings on fecal mass were surprising. We expected that increased fermentation would lead to an 
increase of total microbial mass. As this microbial mass is estimated to be about 55% of the total 
fecal solids, a fecal weight change was anticipated (Stephen & Cummings, 1980). Ito et al (1990) 
investigated the effects of administrating galacto-oligosaccharides on different variables. No 
changes in fecal weights were observed after testing different doses of galacto-oligosaccharides 
using a strict study design. Gibson et al (1995a) showed a trend towards higher fecal wet and dry 
weights. Since the excretion of nitrogen was significantly higher during supplementation with 
fructo-oligosaccharides, the authors concluded that the increase in fecal weight was probably due to 
an increase in biomass. Little effect was shown on total bacterial counts per gram feces. 
The present study was performed under uncontrolled dietary conditions and therefore 
correction for dietary fiber intake was impossible. The bulking capacity of dietary fiber might have 
influenced the fecal weights in this study (Cummings et al, 1992) and possibly masked the effect of 
biomass on fecal weight. Moreover, it should be noted that fiber intakes were relatively high 
compared with the average intake by Dutch men of the same age category (40 g/d v. 27 g/d) 
(Anonymous, 1988). This is also reflected in the daily stool output (mean 270 g/d) which is 
considerably higher than reported values for healthy male adults in the UK (mean 122 g/d) 
(Cummings et al, 1992). 
In general, the volunteers accepted the sweet taste of fructo-oligosaccharides well. The only 
negative remark concerned the increase in flatulence during SF15 supplements. 
The fructo-oligosaccharide supplements were marked with lithium in order to check compliance of 
intakes. Lithium recovery was 82% during SF15, which was significantly lower than the 90% 
recovery during control. If this was due to a lower intake of SF15, then the intake of fructo-
oligosaccharides at this level might not have been 15 g, but between 13.5 and 14 g/d. This would 
still have been high compared with the estimated daily consumption of fructo-oligosaccharides, 
which is only about 1 g/d (Spiegel et al, 1994). 
We conclude that fructo-oligosaccharides added to the diet of young Western subjects are 
fully metabolized in the large intestine. The next step is to study in depth the specific effects of 
supplementation with fructo-oligosaccharides on microfloral growth and metabolism. Gibson et al 
(1995a) recently reported interesting results suggesting that supplementation with oligosaccharides 
might lead to the establishment of a more healthy colonic community, through the selective 
stimulation of bifidobacteria. 
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Abstract 
Patients with large bowel diseases may undergo ileal pouch-anal anastomosis, in which the colon is 
removed and part of the distal ileum is used to construct a pelvic reservoir. Competence of the ileal 
pouch to ferment carbohydrates is associated with the absence of pouchitis. However, the extent to 
which bacterial fermentation takes place and whether it is affected by diet are unclear. We 
investigated fermentation of two nondigestible carbohydrates, fructo-oligosaccharides and resistant 
starch, in 15 healthy patients with an ileal pouch by using a placebo-controlled crossover design 
(with glucose as a placebo). Apparent fermentability of fructo-oligosaccharides was 83%; that of 
resistant starch was 46%. Resistant starch increased fecal excretion of butyrate by 69% whereas 
fructo-oligosaccharides reduced excretion of the amino acid-derived isobutyrate by 94% and of 
isovalerate by 77%. Fructo-oligosaccharides also significantly increased fecal weight (651 
compared with 541 g/d) and breath hydrogen excretion (286 compared with 85 ppm x h). Bacterial 
fermentation of nondigestible carbohydrates in pouches takes place to an appreciable extent and in a 
substrate-specific manner. The relation between such fermentation and inflammation of the pouch 
(pouchitis) deserves study. 
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Introduction 
Excision of the colon followed by ileal pouch-anal anastomosis has become a frequently used 
surgical alternative to permanent ileostomy in patients with ulcerative colitis or familial 
adenomatous polyposis. In this operation part of the distal ileum is used to construct a reservoir or 
pouch that is connected to the anus and provides a measure of continence. 
In the months or years after surgery, the pouch gradually acquires a bacterial content and 
mucosal morphologic characteristics that indicate that the pouch has taken over some colonic 
functions. Morphological adaptation of the ileal tissue of the pouch often results in transformation 
to colonic-type mucosa (de Silva et al, 1991; Tonelli et al, 1991; Campbell et al, 1994). Stasis of 
the luminal contents in the pouch probably promotes colonization by bacteria. Pouch effluent 
contains more anaerobic bacteria than does ileostomy effluent (nasmyth et al, 1989; Santavirta et al, 
1991). Several studies showed considerable excretion of fecal short-chain fatty acids in pouch 
effluent (Mortensen et al, 1989; Nordgaard et al, 1993; Clausen et al, 19926; Nasmyth et al, 1989; 
Ambroze et al, 1993) and, in one study, a breath-hydrogen response after consumption of the 
synthetic disaccharide lactulose was observed in half of the patients (Bruun et al, 1995). Short-chain 
fatty acids and hydrogen are both end products of fermentation and thus indicate the presence of an 
active bacterial mass in an ileal pouch. 
In healthy humans fermentation depends to a high degree on the composition of the diet and 
availability of substrates to the intestinal microflora (Cummings & Englyst, 1987a). However, little 
or nothing is known about the fate of nondigestible dietary compounds in an ileal pouch and the 
extent to which bacterial fermentation takes place. 
We therefore studied fermentation of two carbohydrates that are not digested or absorbed in the 
small intestine: fructo-oligosaccharides and resistant starch. We provided these carbohydrates as 
supplements to diets of patients with an ileal pouch-anal anastomosis. Fructo-oligosaccharides 
occur naturally in, for example, onions and leeks (Spiegel et al, 1994; Roberfroid et al, 1993; Van 
Loo et al, 1995). We used a native resistant starch that is enclosed in granules such as those in raw 
potatoes or unripe bananas (Englyst et al, 1992). In vitro studies showed that the end products of the 
fermentation of fructo-oligosaccharides are gases, such as hydrogen, and short-chain fatty acids, 
mainly acetate (Wang & Gibson, 1993). Resistant starch is a good substrate for production of 
butyrate (Wang & Gibson, 1993), the major fuel of colonic mucosa. In healthy humans, fructo-
oligosaccharides are fermented rapidly whereas resistant starch has a slow, prolonged fermentation 
(Munster et al, 1994a; Rumessen et al, 1990; Stone-Dorshow & Levitt, 1987). Thus, these two 
carbohydrates span the range of fermentability in subjects with a normal gastrointestinal tract, 
which makes them suitable for examining the extent to which fermentation takes place in patients 
with an ileal pouch. 
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The following hypotheses were tested: 1) fructo-oligosaccharides are fermented more extensively 
than is resistant starch, as reflected in recovery of fructo-oligosaccharides and resistant starch in 
pouch effluent; 2) fructo-oligosaccharides increase breath hydrogen excretion and total fecal 
excretion of short-chain fatty acids, especially acetate, and decrease excretion of the amino acid-
derived short-chain fatty acids; and 3) resistant starch increases breath hydrogen excretion and total 
fecal excretion of short-chain fatty acids, especially butyrate. 
Subjects and methods 
Subjects and experimental design 
We recruited 16 patients (8 men and 8 women) who had undergone ileal pouch-anal anastomosis 
because of ulcerative colitis (n=15) or familial polyposis (n=l). Time since the operation was > 12 
months. The patients had never had clinical signs of pouchitis and were not treated with antibiotics 
for > 3 months before the experiment. Subjects were asked to maintain their habitual medication 
regimen (strictly the same quantities) during the experiment. Five subjects took loperamide (4-16 
mg/d) throughout the study; one subject also took prednisone (10 mg/d) and metformin (1500 
mg/d). Two subjects smoked and one consumed a lactose-free diet. No subjects were vegetarian. 
The study protocol was approved by the Ethical Committee of the University Hospital St Radboud, 
Nijmegen, Netherlands. All subjects gave informed written consent before participating. After 
completing the study, patients received a small financial reward, the amount of which was based on 
the time they had spent on the experiment. 
The study was a single-blinded, completely balanced, three period crossover trial with 
supplement periods of 7 d separated by 7-d wash-out periods. Each volunteer took each of three 
different supplements in random order. Fecal and breath samples were collected at the end of each 
supplement period. Subjects kept a diary in which they recorded stool frequency, possible diseases 
or discomfort, medications used, and deviations in eating, drinking or lifestyle behavior. 
Supplements and food intake 
Subjects were asked not to eat probiotic dairy products, which contain microorganisms able to 
survive passage through the upper gastrointestinal tract, or foods containing large amounts of 
fructo-oligosaccharides or resistant starch, such as beans, leeks, and onions. Subjects were given a 
list of these foods. 
Participants recorded their habitual diet for two days in every supplement period. These food 
records were coded and nutrient and energy intakes were calculated with use of a modified version 
of the 1993 Netherlands Nutrient Data Bank (Anonymous, 1993a). 
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Fructo-oligosaccharides 
g/d 
14.3 
-
0.7 
10.8 
Resistant starch 
-
14.3 
11.5 
-
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Composition of the supplements is shown in table 1. Subjects consumed half of each supplement at 
breakfast and the other half at dinner. Supplements were mixed with yoghurt, pudding or orange 
juice; no change in vehicle was allowed during the experiment. All supplements provided a total of 
25.8 g carbohydrates/d. The fructo-oligosaccharide and resistant starch supplements each contained 
14.3 g of nondigestible carbohydrates; the remainder was either digestible or readily absorbable. 
Table 1. 
Composition of the dietary supplements 
Placebo 
Fructo-oligosaccharides1 
Resistant starch2 
Digestible carbohydrates3 
Added glucose4 25.8 
1
 Raftilose P95®, Orafti, Tienen, Belgium; contains 95% oligosaccharides by weight as measured by the 
method described in this paper. 
2
 Hylon VII, Nat. Starch and Chemical Company, Bridgewater NJ, USA; contains 55.4% resistant starch by 
wt as measured in vitro according to the method of Englyst et al (1992). 
3
 Other carbohydrates present in Raftilose P95® and Hylon VII, were mainly glucose, fructose, sucrose and 
digestible starch. 
4Glucose Pur 01934, Cerestar Benelux BV, Sas van Gent, The Netherlands. 
Breath samples 
On the final day of each supplement period, subjects collected end expiratory breath samples at 2-
or 3-h intervals from 08:00 (before eating) to 22:00 and again at 08:00 (before eating) the next 
morning. They used plastic 60-mL syringes (Sherwood, Ballymoney, Ireland) that were sealed and 
stored at 4 °C immediately after the sampling. Contents of the syringes were analyzed for hydrogen 
concentration by using a standard electrochemical cell (Lactoscreen, Hoekloos, Amsterdam, 
Netherlands) within 24 h after the first sample was obtained. The cell was calibrated with a standard 
containing 100 ppm hydrogen in air (AGA Gas BV, Amsterdam, Netherlands). The 24 h integrated 
breath-hydrogen excretion was estimated by calculating geometrically the area under the curve of 
concentration in relation to time (Wolever & Jenkins, 1986). 
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Stool Collection and Fecal Analyses 
On the last day of each supplement period, subjects collected feces for 24 h and stored each stool 
immediately on dry ice. We collected stools at subjects' homes and stored them at -20°C. Feces 
were thawed overnight at 4 °C, weighed, pooled, and homogenized by using a bowl and mixer. The 
proportion of fecal dry material was estimated by freeze-drying aliquots in triplicate. Another 
aliquot was ultracentrifuged at 30000 x g for 120 min at 4°C for preparation of the aqueous fraction 
of stool. Fecal water was pipetted off and filtered through a 5 um filter (Schleicher & Schuell, 
Dassel, Germany). The pH of the fecal water was determined and samples were stored at -20 °C. 
Concentrations of short-chain fatty acids in fecal water were measured in duplicate as described 
by Tangerman et al (1996), by using gas chromatography (Chrompack Model CP 9001, 
Middelburg, Netherlands) and a column packed with 10% SP1200 silicone stationary phase and 1% 
H3P04 on an 80-100 Chromosorb W acid-washed instrument (Chrompack). An internal standard 
was added to all samples before analysis (15 mmol 2-ethylbutyric acid/L in 100% formic acid). 
Fecal excretion of short-chain fatty acids was calculated as fecal weight X proportion of fecal wet 
material X concentration of short-chain fatty acids in fecal water. In this calculation, the proportion 
of fecal wet material was defined as 1 minus the proportion of fecal dry material. 
Fructo-oligosaccharides in feces were measured in duplicate samples of 125 mg freeze dried 
feces resuspended in 2.4 mL distilled water. D-galacturonic acid (100 uL, 0.5% wt:vol) was added 
as an internal standard before extraction. The mixture was vortexed and heated for 15 min at 100°C 
and then centrifuged at 13000 x g for 30 min. The supernate was analyzed by high-performance 
anion-exchange chromatography (Dionex BV, Breda, Netherlands) by using a programmable pulse 
electrochemical detector, a Carbopack PA-100 analytical column (4*250 mm, Dionex) and a mobile 
phase consisting of 0.1 mol NaOH/L (A) and 1 mol Na-acetate/L containing 0.1 mol NaOH/L (B). 
A linear gradient was used from 100% A to 70% A plus 30% B in 25 min with a flow rate of 1 
mL/min. A calibration curve was made with purified isokestose, which is one of the oligomers in 
the fructo-oligosaccharide supplement used in the study. Quantification of fructo-oligosaccharides 
in feces was based on this curve and a correction factor was obtained by comparing a known 
quantity of fructo-oligosaccharides with the calculated value. 
Total starch in stools was determined by subtracting the amount of free glucose from the total 
amount of glucose obtained after incubation with a starch-degrading enzyme. This method was 
modified of that ofBjork et al (1987). Fifty milligrams freeze-dried feces was suspended in 2 mL 
water and heated for 5 min at 100°C; free glucose was then measured with a test kit (catalog no. 
716251, Boehringer Mannheim GmbH, Mannheim, Germany). For analysis of total glucose, 
defined as the sum of starch and free glucose, 50 mg of freeze-dried feces was suspended in 1 ml 
water and 1 ml of a solution containing 4 mol KOH/L and incubated for 30 min at room 
temperature. The suspension was neutralized with hydrochloric acid and diluted (1:1) with 0.4 mol 
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Na-acetate buffer/L (pH 4.75). The mixture was incubated with 20 i^l amyloglucosidase (1.4 x 105 
U/L, Boehringer Mannheim) for 30 min at 60 °C to hydrolyze the starch and centrifuged for 15 min 
at 1000 x g. Glucose in the supemate was determined by using the test kit. The amount of starch 
was calculated as the difference between total and free glucose. Mean recovery of starch if added to 
fecal samples before treatment of the samples was 102%. The CV between separately treated and 
measured duplicates was 8%. 
Data Analysis 
Results are expressed as means and standard errors, unless stated otherwise. The distribution of 
individual differences was checked for normality by visual inspection of the normal probability 
plots (univariate procedure, SAS Institute Inc. Cary, NC). The significance of the differences 
between treatments was assessed by analysis of variance without interactions using a model with 
subject and supplement (general linear models procedure). Adding period to this model did not 
contribute to the significance; thus there were no significant effects of time or sequence. In there 
was a significant difference between treatments (P < 0.05), group means were compared using the 
Tukey test if the model was orthogonal or the Scheffe test if there were missing values in the data 
set (general linear models procedure). Conventional Pearson's correlation coefficients (correlation 
procedure) were used to assess the relations between dependent variables. 
Results 
Characteristics of subjects who completed the study and dietary intakes during the study are given 
in table 2. 
One subject withdrew at the end of the first washout period because of an endoscopically 
confirmed pouchitis; data from this subject were excluded from analyses. One subject did not 
complete the third supplement (fructo-oligosaccharides) period because of gastrointestinal 
complaints such as vomiting. For this subject we excluded only data from the fructo-
oligosaccharide period from analyses. All other subjects completed the study without illness. Most 
subjects had flatulence during fructo-oligosaccharide supplementation; no other gastrointestinal 
problems were reported. There were no reports of problems with palatability of the supplements. 
The food records showed no changes in average daily intakes of energy, protein, fat, carbohydrates 
or dietary fiber between treatments. 
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Table 2. 
Patient characteristics and background diets1 
Characteristics 
Age (y) 
Height (m) 
Weight (kg) 
Body mass index (kg/m2) 
Diet2 
Energy (MJ/d) 
Carbohydrate (% of energy) 
Fat (% of energy) 
Protein (% of energy) 
Dietary fiber intake (g/d) 
Men 
(n=7) 
35.6 ± 6.5 
1.80 ± 0.1 
80.9 ± 10.4 
25.0 ± 3.0 
12.1 ± 1.3 
45.1 ± 4.3 
37.1 ± 4.3 
15.0 ± 2.4 
20.0 ± 6.6 
Women 
(n=8) 
36.5 ± 7.8 
1.66 ± 0.1 
66.4 ± 10.2 
24.1 ± 4.1 
8.9 ± 0.6 
44.0 ± 6.0 
37.9 ± 4.7 
17.9 ± 3.6 
13.5 ± 7.3 
1
 Mean ± SD. 
2
 Supplements not included; maximal contribution of supplements to energy intake was 0.45 MJ/d. 
Bowel habit and stool composition 
Data on bowel habits, fecal weight, fecal pH and fecal excretion of fructo-oligosaccharides and 
resistant starch are given in table 3. There was no fecal excretion of fructo-oligosaccharides in any 
subject taking placebo. During fructo-oligosaccharide supplementation, mean excretion was 2.4 g/d 
(95% CI, 1.1 to 3.7) or 17% of the supplemented dose. All constituents of the fructo-
oligosaccharide supplement (table 1) were present in the feces; thus no selective breakdown of 
specific oligomers was observed. The fecal excretion of starch was 7.7 g higher per day while 
subjects were taking the resistant starch supplement than when they were taking placebo (95% CI, 
5.1 to 10.4). Because 14.3 g resistant starch/d was added to the diet, 46% of dietary resistant starch 
was broken down in the alimentary tract. 
Fructo-oligosaccharides increased mean stool frequency by 9% and fecal weight by 20% or 110 
g/d. Percentage of dry matter was not affected by fructo-oligosaccharides but fecal excretion of dry 
matter increased by 28.8 g/d (95% CI, 9.5 to 48.1; P = 0.0009). In subjects taking resistant starch, 
values for mean stool frequency, fecal weight and fecal dry matter all tended to be slightly higher 
than placebo values, but the differences were not significant. Fecal water pH tended to be lower 
(although not significantly) in subjects taking fructo-oligosaccharides (95% CI, -0.4 to 0.1 pH-units) 
or resistant starch (95% CI, -0.4 to 0.1 pH-units) than in those taking placebo. 
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Short-chain fatty acids 
Fecal excretion of various short-chain fatty acids during the three treatments is shown in table 4. 
Total amount of short-chain fatty acids excreted tended to be somewhat, although not significantly, 
higher during supplementation with fructo-oligosaccharides (95% CI, -3.4 to 7.6 mmol/d) or 
resistant starch (95% CI, -0.1 to 10.7 mmol/day) than with placebo. During supplementation with 
resistant starch, excretion of butyrate was elevated by 69% (P = 0.0014). Isobutyrate excretion was 
lowered by 94% (P = 0.0006) and isovalerate excretion by 77% (P = 0.0023) during fructo-
oligosaccharide supplementation. We detected no caproate in any of the fecal samples. There was a 
negative correlation between number of stools per day and total excretion of amino acid-derived 
short-chain fatty acids (r = -0.36; P < 0.05). 
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Figure 1. Mean breath-hydrogen concentration on the seventh day of supplementation with placebo 
(•), fructo-oligosaccharides (•), or resistant starch (A). Bars on the horizontal axis indicate time of 
ingestion of supplement. 
Breath hydrogen 
Breath-hydrogen curves over the last 24 hours of each supplement period are shown in figure 1. 
Integrated breath-hydrogen excretion expressed as area under the hydrogen-time curve, was higher 
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during fructo-oligosaccharide supplementation (286 ± 84 ppm x h) than during placebo 
consumption (85 ± 17 ppm x h, P = 0.004). Hydrogen excretion during resistant starch 
supplementation was elevated by 125 ppm x h (95% CI, -23.0 to 273.4) but the difference with 
placebo was not significant (P = 0.046) when the significance limit was corrected for multiple 
comparisons. There was no correlation between individual values for integrated breath-hydrogen 
excretion and fecal excretion of fructo-oligosaccharides (r = -0.14; P = 0.46) or resistant starch (r = -
0.09; P = 0.64). 
Discussion 
We found that fructo-oligosaccharides and resistant starch, two nondigestible carbohydrates 
commonly found in foods, are well fermented in patients with an ileal pouch-anal anastomosis. To 
our knowledge this was the first quantitative study of carbohydrate fermentation in this patient 
group. 
Apparent fermentability of fructo-oligosaccharides and resistant starch 
The mean recovery of fructo-oligosaccharides in feces was 17% of the daily dose of supplement. 
Fructo-oligosaccharides are not metabolized by human digestive enzymes and most fructo-
oligosaccharide molecules survive passage through the upper part of the gastrointestinal tract 
(Nilsson & Bjorck, 1988; Oku et al, 1984; Tokunaga et al, 1995; Bach Knudsen & Hessov, 1995; 
Molis et al, 1996). It is thus likely that most fructo-oligosaccharides in our study were fermented by 
bacteria in the ileum or pouch. No fructo-oligosaccharides were recovered from feces of any subject 
taking placebo, probably because of low amounts of fructo-oligosaccharides in the background diet 
(Spiegel et al, 1994; Roberfroid et al, 1993; Van Loo et al, 1995). In a previous study (Fleming et 
al, 1988) we found no fructo-oligosaccharides in feces of healthy men after supplementation with 
15 g fructo-oligosaccharides (Alles et al, 1996). Thus colonic bacteria are evidently capable of 
fermenting 100% of fructo-oligosaccharide supplements in subjects with a complete colon. In our 
subjects with a pouch, the proportion was 83%. 
Man fecal excretion of residual starch during placebo consumption was 5 g, which can be 
attributed to resistant starch present in the background diet. Average recovery of resistant starch 
from the supplemented dose was 54%. In healthy subjects, * 20-30% of resistant starch supplement 
was recovered from feces (Philips et al, 1995). Patients with a pouch thus had more efficient 
fermentation of fructo-oligosaccharides than of resistant starch, but both nondigestible 
carbohydrates were fermented less extensively in such patients than in subjects with an intact colon. 
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Bowel habit and stool composition 
An ileal pouch has a much smaller mucosal surface available for water resorption and a smaller 
volume than an intact colon. Thus, luminal contents that pass the pouch are relatively large as 
compared with those in an intact colon. The pouch thus fills up sooner, which results in a shorter 
stasis time of the luminal content, and faster transit (Oresland et al, 1990; de Silva et al, 1991). Low 
resorption of water from luminal contents causes a high stool weight and a lower proportion of dry 
matter than in subjects with an intact colon. During placebo supplementation, the mean fecal wet 
weight was 541 g/d with 12.5% dry matter. Fructo-oligosaccharides significantly increased 24 h 
fecal weight and fecal dry mass, although < 10% of the increase in fecal mass consisted of 
unfermented fructo-oligosaccharides. The proportion of fecal wet material was not affected by the 
fructo-oligosaccharides; therefore the increased fecal weight was probably not caused by an osmotic 
effect of fructo-oligosaccharide molecules. It is more likely due to an increase in fecal biomass, 
which is also found in healthy subjects (Gibson et al, 1995a). 
Administration of resistant starch did not significantly alter fecal wet or dry weights. 
Unfermented resistant starch would be expected to have its greatest effect on fecal dry weight. 
Because of the lower apparent fermentability of resistant starch a smaller effect on biomass, 
reflected in fecal wet weight, might be expected. Intra-individual week-to-week variations in fiber 
intake possibly masked a small effect of resistant starch on dry weight and biomass. 
The brief duration of stasis of the luminal contents in the pouch was also reflected in the 
frequency of defecation. During the control period, the patients reported a mean of 6.5 stools/d, 
which is similar to quantities found by other researchers (Nordgaard et al, 1993; Clausen et al, 
19926; Salemans et al, 1992). During the fructo-oligosaccharide supplementation, the frequency 
was even higher, probably as a result of the higher stool volumes. The mean time between pouch 
voidings was < 4 h. This interval was obviously long enough to allow bacteria to degrade most of 
the supplemented fructo-oligosaccharides. Because the fermentation of resistant starch is relatively 
slow, the interval between voidings may have been too short for microflora to ferment the resistant 
starch more extensively. 
Breath hydrogen and fecal short-chain fatty acids 
Bacterial degradation of fructo-oligosaccharides and resistant starch was reflected in the 
production of hydrogen and short-chain fatty acids. Bruun et al (Bruun et al, 1995) observed an 
increase in breath hydrogen in half of patients with a pouch who took the synthetic nondigestible 
disaccharide lactulose (10 g). Only 2 of the 15 subjects in that study had a hydrogen response to 
wheat starch. Those who did not respond to lactulose had poor functional pouch characteristics, 
such as incontinence. The authors concluded that fermentation of lactulose is associated with better 
pouch function. 
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In our study fructo-oligosaccharides increased hydrogen excretion by 236% relative to placebo 
values and resistant starch increased the hydrogen excretion by 147%. During supplementation with 
either fructo-oligosaccharides or resistant starch, half of the subjects did not respond, that is their 
hydrogen concentrations in expired air were never > 10 ppm. We did not find any significant 
correlations between hydrogen excretion and recovery of fructo-oligosaccharides or resistant starch 
in feces. This may indicate that the hydrogen response was determined by factors other than the 
mass of carbohydrates fermented. However, because of the small number of patients and the small 
range in fecal carbohydrate excretion, we may have missed a modest association. 
Our data do not allow firm conclusions about the effect of either fructo-oligosaccharides or 
resistant starch on the total amount of short-chain fatty acids or on fecal pH. Short-chain fatty acids 
are produced simultaneously with hydrogen by most bacteria (Cummings & MacFarlane, 1991). 
MacFarlane et al (1992), in an autopsy study of victims of sudden death, found high amounts of 
short-chain fatty acids in the proximal colon and lower amounts toward the end of the 
gastrointestinal tract. They attributed this to rapid absorption of these acids by the colonic mucosa. 
A similar absorption by the pouch mucosa could explain why we did not find significant effects on 
total excretion of short-chain fatty acids or on pH in our study. We observed trends towards a 
greater excretion of total short-chain fatty acids, a greater excretion of acetate and a lower fecal pH, 
but our study probably lacked the power to detect small effects on these variables. Tonelli et al 
(Tonelli et al, 1995) found no increase in fecal short-chain fatty acids after administration of short-
chain fatty acids into the pouch. They concluded that a rapid absorption by pouch mucosa was 
probably responsible. 
Fructo-oligosaccharides significantly depressed excretion of isobutyrate and isovalerate. These 
short-chain fatty acids originate from the bacterial breakdown of amino acids (MacFarlane & 
MacFarlane, 1993; Rasmussen et al, 1988; Zarling & Ruchim, 1987). Similar effects were observed 
in healthy men given galacto-oligosaccharides (Ito et al, 1993a) or lactulose (Ito et al, 19936; 
Mortensen et al, 1990). Protein fermentation was thus apparently depressed by the addition of a 
rapidly fermentable carbohydrate. Protein fermentation produces not only amino acid-derived short-
chain fatty acids, but also indoles and ammonia. These products might have a toxic effect on 
mucosa (Prior et al, 1974; Lin & Visek, 1991; Clinton et al, 1988). Therefore, we suggest that 
adding fructo-oligosaccharides to the diet of patients with an ileal pouch-anal anastomosis might 
decrease the cytotoxicity of pouch contents. 
Resistant starch increased the excretion of butyrate, an effect also found in studies in healthy 
subjects (Mcintyre et al, 1991; Philips et al, 1995). Butyrate is a major fuel for the colonic mucosa 
and may inhibit cell proliferation and stimulate cell differentiation. Moreover, it was suggested that 
ulcerative colitis is caused by diminished oxidation of butyrate (Roediger, 1980). Additionally, 
Nasmyth et al (1989) observed a negative correlation between concentration of butyrate in pouch 
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effluent and the severity of villous atrophy of pouch mucosa. Thus, it may be worthwhile to study 
the potentially beneficial effects of dietary resistant starch in patients with pouch inflammation. 
Inflammation of the ileal pouch, pouchitis, is often regarded as a new manifestation of 
ulcerative colitis, because pouchitis is far more common in patients who were operated on because 
of ulcerative colitis than in those operated on because of familial adenomatous polyposis (Salemans 
et al, 1992; Shepherd, 1995). In this study we intended to study fermentation in a group of healthy 
patients with an ileal pouch-anal anastomosis. Patients had never had any clinical signs of pouchitis 
but we did not confirm the absence of pouchitis by endoscopic or histologic examinations of the 
pouch. Moreover, some of the patients were taking medications (loperamide and prednisone) that 
could have masked symptoms of pouchitis. As a result we might have included unintentionally 
some patients with pouchitis in our study. 
Bacterial overgrowth was previously considered a cause of pouchitis (Santavirta et al, 1991; 
nasmyth et al, 1989; Sandborn et al, 1995). There is, however, no theoretical foundation for such an 
effect. Additionally, bacterial overgrowth of the pouch is present in virtually all patients with a 
pouch, independent of the presence or absence of pouchitis. Microbial analyses of pouch effluents 
did not show higher bacterial counts in patients with pouchitis compared to those without 
(O'Connell et al, 1986; Kmiot et al, 1993; Luukkonen et al, 1988). Thus bacterial growth does not 
contribute to pouchitis. In fact, there are indications that the pouch flora may help to maintain pouch 
health. A relative increase of aerobic bacteria and a decreased production of short-chain fatty acids, 
both possibly caused by a low supply of fermentable saccharides, were associated with pouchitis 
(Clausen et al, 1992ft). Also, Bruun et al (Bruun et al, 1995) found that the ability to ferment 
lactulose, measured as a breath hydrogen response, was associated with a better pouch function. 
Conclusion 
Ileal pouch flora was competent to ferment nondigestible dietary carbohydrates. Fructo-
oligosaccharides were largely fermented, and they depressed protein fermentation. Resistant starch 
caused an increase in excretion of butyrate. It appears justified to study the effects of such dietary 
carbohydrates on the development of pouchitis. 
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Effect of transgalacto-oligosaccharides on composition 
and activity of the intestinal microflora 
Martine S. Alles, Ralf Hartemink, Saskia Meyboom, Jan L. Harryvan, Katrien M.J. Van Laere, 
Fokko M. Nagengast, Joseph G.A.J. Hautvast. Submitted for publication. 
Abstract 
Non-digestible oligosaccharides have been claimed to benefit the health of the colon by selectively 
stimulating the growth of bifidobacteria and by decreasing the toxicity of the colon content. We 
studied the effect of 2 doses of transgalacto-oligosaccharides on the composition and activity of the 
intestinal microflora in 18 women and 22 men as compared to a placebo. Strictly controlled 
experimental diets were supplied to three intervention groups (parallel design). The study was 
divided into two consecutive 3-week periods with participants consuming a run-in followed by an 
intervention diet which differed only in the amount of transgalacto-oligosaccharides: 0 g/d 
(placebo), 7.5 and 15 g/d. Breath and fecal samples were collected at the end of both run-in and 
intervention periods. Apparent fermentability of transgalacto-oligosaccharides was 100%. The 
highest dose of transgalacto-oligosaccharides significantly increased the concentration of breath 
hydrogen by 138% (P < 0.01) and the nitrogen density of the feces by 6.5% (P < 0.05). The number 
of bifidobacteria increased on both placebo and transgalacto-oligosaccharides, but the increases 
were not significantly different. Transgalacto-oligosaccharides did not affect bowel habits, stool 
composition, the concentration of short-chain fatty acids or bile acids in fecal water, the 
concentration of ammonia, indoles or skatoles, fecal pH or the composition of the intestinal 
microflora. We conclude that transgalacto-oligosaccharides are completely fermented in the human 
colon, but do not beneficially change the composition of the intestinal microflora, the amount of 
protein fermentation products in feces or the profile of bile acids in fecal water. 
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Introduction 
The recent commercialization of non-digestible oligosaccharides as food ingredient has triggered 
much research on their role in colonic health. Non-digestible oligosaccharides naturally occur in 
various edible food plants such as onions and leek (Van Loo et al, 1995). As they are not 
hydrolyzed by enzymes in the human small intestine, they reach the colon intact. Oligosaccharides 
are relatively small molecules. In a previous study we showed that fructo-oligosaccharides, added to 
the diet of young healthy subjects are fully fermented by the colonic microflora (Alles et al, 1996). 
Colonic fermentation is the anaerobic process in which carbohydrates and proteins are 
metabolized by the intestinal microflora. End-products of fermentation are substrate-dependent. 
Fermentation of carbohydrates will mainly lead to the production of gases, the short-chain fatty 
acids acetate, butyrate and propionate, and sometimes of lactate or ethanol. Protein fermentation 
increases the branched chain fatty acids iso-butyrate and iso-valerate, phenolic compounds and 
ammonia (MacFarlane & MacFarlane, 1993; Cummings & MacFarlane, 1991). The colonic 
fermentative activity is regulated by the amount and type of substrate that enters the colon, such as 
endogenous compounds and undigested food components (Cummings & MacFarlane, 1991). It 
seems likely that the composition of the diet is of influence on the activity of the intestinal 
microflora. 
Transgalacto-oligosaccharides are produced from lactose by enzymatic transgalactosylation. 
The oligomers consist of lactose and several galactose molecules with mainly 13-1,4 linkages 
(Yanahira et al, 1995). Transgalacto-oligosaccharides are not hydrolyzed by human small-intestinal 
13-galactosidase and will pass undigested into the colon (Burvall et al, 1980). Tanaka et al reported 
already in 1982 that administration of transgalacto-oligosaccharides leads to an increase in breath 
hydrogen excretion because of its non-digestibility. Moreover, they showed that transgalacto-
oligosaccharides might stimulate the growth of resident bifidobacterial strains (Tanaka et al, 1983). 
Ten years later, these results were confirmed by studies of Ito et al (1990; 1993a) and Bouhnik et al 
(1997). 
Bifidobacteria may comprise up to one quarter of the gut flora of normal healthy adults 
(Modler et al, 1990). They have a role in controlling the pH of the large intestine, through the 
production of lactic and acetic acid. A low pH might restrict the growth of many potential 
pathogens and putrefactive bacteria (Modler et al, 1990; Gibson & Wang, 1994) and might both 
depress the formation of secondary from primary bile acids and enhance the precipitation of bile 
acids (Munster et al, 19946; Rafter et al, 1986; Nagengast et al, 19886; Hofmann & Mysels, 1992). 
It thus seems important to identify food components that have a potential in increasing the number 
of indigenous bifidobacteria. 
Most studies looking at the effects of transgalacto-oligosaccharides on bifidobacteria used a 
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linear study design and did not exclude possible time and placebo effects. Also, the focus was 
always on the composition of the intestinal flora and not on possible colon cancer risk markers such 
as stool weight (Cummings et al, 1992), bile acids (Reddy et al, 1992; Lapre & Meer, 1992) and 
putrefactive products (Clinton et al, 1988; Prior et al, 1974; Lin & Visek, 1991). We used a 
controlled feeding trial to study the effect of two doses of transgalacto-oligosaccharides as 
compared with a placebo on the composition of the intestinal microflora, the saccharolytic and 
proteolytic activity of the bacteria and on the profile of bile acids in fecal water. 
Subjects and methods 
Subjects 
Volunteers were recruited via advertisements in local newspapers and posters mounted in public 
buildings in Wageningen. The experiment was preceded by a screening procedure comprising a 
health questionnaire, blood and urine analyses, a transgalacto-oligosaccharides tolerance test and a 
lactose breath test. Sixty-three volunteers started with the screening procedure. Five volunteers 
withdrew before the start of the study. 
Biomedical inclusion criteria were as follows: age between 18 and 75, stable body weight, 
no (history of) gastrointestinal or gallbladder disorders, no use of antibiotics or laxatives in the 12 
months prior to the experiment, not operated on in the 12 months prior to the experiment, no 
complaints of diarrhea, obstipation or abdominal pain, no use of medication known to affect 
gastrointestinal function, serum cholesterol concentration < 7.0 mmol/L, serum triacylglycerol 
concentration < 2.5 mmol/L, normal hemocytometric values, normal urinary values for protein, 
glucose and pH. Five volunteers were excluded because of biomedical reasons. 
A lactose breath test was performed to exclude hydrogen responders to lactose. Subjects 
came to the department after an overnight fast and consumed a drink with 50 g of lactose. Breath 
samples were taken before and at 30 minutes intervals after the lactose-drink. An increase in the 
concentration of breath hydrogen of 15 ppm above baseline was used as an exclusion criterion. 
Twelve volunteers showed hydrogen responses to lactose, probably because of lactase deficiency, 
and were excluded from the study. 
Subjects were challenged with a single dose of 10 g of transgalacto-oligosaccharides to 
check for possible intolerance. None of the volunteers showed any signs of intolerance or 
discomfort. None of the volunteers was excluded because of intolerance. Forty-one volunteers (19 
women and 22 men) entered the study. 
The study protocol was approved by the Medical Ethics Committee of the Division of 
Human Nutrition and Epidemiology. The protocol and aims of the study were fully explained to the 
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volunteers, who gave their informed written consent. The food was free during the experiment and 
after successfully completing the study, the volunteers received a small financial reward. 
Design 
The study was conducted using a six weeks parallel trial with three intervention groups. The study 
was divided into two consecutive 3-week periods during which each participant consumed a run-in 
diet in the first 3-week period and an intervention diet in the last 3-week period. The interventions 
consisted of either a diet high in transgalacto-oligosaccharides (aimed to be 15 g/d, high-TOS), or a 
diet with a low amount of transgalacto-oligosaccharides (aimed to be 7.5 g/d, low-TOS), or a diet 
with no transgalacto-oligosaccharides (placebo). At the end of the run-in and intervention period, 
fecal samples and breath samples were collected. The group was divided into 3 start-groups, each 
starting one week after the other, to be able to handle all fresh fecal samples at the laboratory. The 
interventions were equally distributed over the start-groups. 
Diets 
Before the trial, trained dietitians used a questionnaire to ask the subjects about their habitual diets 
(Feunekes et al, 1995; Feunekes et al, 1993). This allowed us to estimate the habitual energy intake 
of the subjects. The questionnaires were coded and diets were calculated by use of the Netherlands 
Food Composition Table (1996). The study diets were formulated at 21 levels of energy intake, 
ranging from 7.5 to 17.5 MJ per day, so that each subject received a diet that met his or her energy 
needs. Body weights were recorded three times weekly, and energy intake was adjusted when 
necessary as to maintain a stable weight. 
The diets consisted of conventional foods, and 21 different menus were provided over the 
course of each 3-week period. The nutrient composition of each diet was similar, except for the 
oligosaccharides. The diets were rich in protein and low in fiber. 
The transgalacto-oligosaccharides (Elix'or®) were provided by Borculo Whey Products, 
Borculo, Netherlands. Fruit juices were used as a vehicle for the interventions and were divided 
over 3 portions of 150 g each and consumed with each meal. Three mixtures were made to add to 
the juices. The high-TOS mixture was based on a transgalacto-oligosaccharides syrup which 
consisted of 75% dry matter of which 60% transgalacto-oligosaccharides with a degree of 
polymerization of 2-8. The remaining dry matter consisted of 20% disaccharides (mainly lactose) 
and 20% monosaccharides (mainly glucose). The low-TOS mixture was composed of the syrup with 
extra glucose and lactose, to correct for the "non-oligosaccharide" components in the syrup. The 
placebo mixture consisted only of glucose and lactose to equal amounts as present in the high-TOS 
and low-TOS mixtures. 
The subjects were blinded to the nature of the intervention by using color codes for labeling 
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the supplied foods. All foodstuffs were weighed out for each subject. On week days at noon, hot 
meals were served and consumed at the department. All other food was supplied daily as a package. 
Food for the weekend and guidelines for its preparation were provided on Fridays. Approximately 
90% of energy intake was from supplied foods, the remaining 10% was from products chosen by 
the subjects from a list of items with no fiber. 
Subjects were urged not to change their selection of free-choice items throughout the study, 
and not to change their smoking habits. The participants kept diaries in which they recorded their 
frequency of defecation, any sign of illness, gastrointestinal complaints, medication used, phase of 
the menstrual cycle, the consumption of free-choice items, and any deviations from their diets and 
in their living behavior. 
Duplicate portions of the diets and the juices were collected every day for an imaginary 
participant with a daily energy intake of 11 MJ, stored at -20 °C, pooled per week and analyzed 
after the study. Records of the free-choice items were coded and their energy and nutrient content 
were combined with the analyzed values of the food supplied. 
To estimate stool recovery, thirty Ba-impregnated grains were swallowed daily together with 
the meals in the last 10 days of run-in and intervention period and were counted back in the fecal 
samples. 
Data collection and analytical procedures 
Data collection 
In the last week of run-in and intervention periods, two breath samples were taken at two 
consecutive days just before lunch. 
In the last week of run-in and intervention periods, volunteers came to the department twice 
to defecate. A button in the study-toilet was pressed immediately after defecation and a light and 
buzzer warned the analyst that a fresh sample was ready to be handled. Temperature of the feces 
was checked and within 5 minutes after defecation, a sample was weighed and transported into an 
anaerobic cabinet. The remaining feces was immediately deep-frozen on dry ice to stop 
fermentation, then stored at -80 °C. In the last weekend of run-in and intervention periods, subjects 
collected all stools and stored them immediately on dry ice. 
Breath hydrogen 
End-expiratory breath samples and ambient air samples were collected in plastic 60 ml syringes 
(Plastipak; Becton Dickinson, Dublin, Ireland). Within 2 h after collection, the hydrogen 
concentration was measured using a standard electrochemical cell (exhaled hydrogen monitor, Gas 
Measurement Instruments Ltd, Renfreq, Scotland). The cell was calibrated with a standard gas of 
100 ppm H2in air. Volunteers refrained from smoking in the hour before the sampling. 
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Preparation of stool samples 
All fecal samples were X-rayed before analysis to determine the number of Ba-grains (Philips 
Optimus M200, Eindhoven, The Netherlands). The samples were then thawed overnight at 4 °C. All 
samples of a single person from each 3-week period were weighted and homogenized in a bowl and 
mixer. Dry weight of the feces was estimated by drying a portion at 80 °C in an oven (Heraeus E45, 
Hanau, Germany) to constant weight. One portion was used for the preparation of the aqueous 
fraction of stool and centrifuged at 26000 g for 90 min at 4 °C (MSE, Scientific Instruments, 
Crawley, Sussex, UK). Fecal water was carefully removed and stored at -20 °C until analysis of 
short-chain fatty acids and bile acids. The pH was measured in both fecal homogenate and fecal 
water with a digital pH meter (CD 620; WPA Ltd. Cambridge, Cambs, UK). One portion of the 
mixed feces was freeze-dried and ground and kept in a dry environment until analysis of nitrogen 
and transgalacto-oligosaccharides. The remaining feces was stored at -20 °C until analysis of 
ammonia, indoles and skatoles. 
Transgalacto-oligosaccharides in feces and juices 
Transgalacto-oligosaccharides were measured in duplicate samples of 125 mg freeze-dried feces re-
suspended in 2.4 mL distilled water. D-galacturonic acid (100 \i\, 1250 ppm) was added as an 
internal standard before extraction. The mixture was vortexed and heated for 15 min at 100 °C and 
then centrifuged at 10.000 g. The supernatant was analyzed by high-performance anion-exchange 
chromatography (Dionex BV, Breda, Netherlands) on a Spectra-Physics system (San Jose, CA, 
USA) equipped with a Carbopac PA-1 column (4x250 mm; Dionex, Sunnyvale, CA, USA). Elution 
was performed with a flowrate of 1 ml/min and a linear sodium acetate gradient of 0 to 0.2 M in 0.1 
M NaOH for 30 min. 
The fruit juices were centrifuged at 10.000 g and the supernatant was analyzed with high-
performance anion-exchange chromatography, using similar conditions as mentioned above, to 
estimate the concentration of transgalacto-oligosaccharides. The elution profile and the areas under 
the peaks of transgalacto-oligosaccharides were compared with that of a water solution with known 
quantities of transgalacto-oligosaccharides. 
Traces of transgalacto-oligosaccharides up to 10 |xg/ml could be detected in fecal water and 
juices. 
Short-chain fatty acids and bile acids in fecal water 
Concentrations of short-chain fatty acids in fecal water were measured in duplicate as described by 
Tangerman et al (Tangerman & Nagengast, 1996) by using a gas chromatograph (model CP 9001; 
Chrompack, Middelburg, Netherlands) and a column packed with 10% SP1200 silicone stationary 
phase and 1% H3P04 on an 80-100 Chromosorb W acid-washed instrument (Chrompack). An 
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internal standard was added to all samples before analysis (15 mmol 2-ethylbutyric acid/L in 100% 
formic acid). Samples of one person were analyzed within one run. 
For the analyses of bile acids, 150 ja.1 of fecal water was freeze-dried and prepared according 
to Glatz et al (Glatz et al, 1985) with a few minor modifications. Samples were analyzed on a 
capillary fused silica column (length 30 m, internal diameter 0.25 mm) coated with CP-Sil-19 CB, 
with a film-thickness of 0.25 (Chrompack, Bergen op Zoom, The Netherlands), by using a Hewlett 
Packard gas chromatograph (model 5890 series II) and Flame Ionisation Detector. Initial pressure of 
the carrier gas (hydrogen) was 90 kPa. Splitless injection was performed using a liquid sampler 
(HP 7673). To cover the wide range of concentrations, injection volumes varied from 0.5 to 2.5 u,l. 
In addition, the levels of calibration solutions were adapted according to the injection volume. The 
initial oven-temperature was 150 °C, then raised to 225 °C immediately after injection and 
increased gradually to 245 °C at a rate of 1 °C /min. The final temperature (275 °C ) was 
maintained for 40 min. The temperature of the injection port was 300 °C and of the detector 275 °C. 
The amount of each bile acid was calculated from area response by using the internal standard 
method with a 7 points multilevel bracketing calibration with pure standards. Samples of one person 
were analyzed within one run. The coefficient of variation within runs was 10% for concentrations 
below 10 |^ mol/L and 5% for concentrations greater then 10 |imol/L. 
Fecal nitrogen, ammonia, indoles and skatoles 
Ammonia was extracted from 5 gram of homogenized feces with perchloric acid (20 ml/ 1M), then 
pH was set to 7 (± 0.1) with KOH (5 M). A commercial test kit (Ammonia UV-method, cat. no. 
1112732; Boehringer Mannheim GmbH, Germany) was used to determine the concentration of 
ammonia. 
Total nitrogen was measured in freeze-dried feces by the Kjeldahl method (Kjeltec 
Autosampler System, 1035 Analyzer, Tecator). 
Indoles and skatoles were extracted from 5 gram of homogenized feces with methanol (50 
ml). The mixture was homogenized using an ultra-turrax (Janke en Kunkel, Tampson, Zoetermeer, 
The Netherlands), then filtered through a glass microfiber filter (Whatman GF/A) before analysis. 
Analyses were performed in duplicate according to the method described by Wilkens (Wilkins, 
1990) using HPLC analysis with ultraviolet absorption detection. 
Microbiological analyses 
Microbiological analyses of each sample were done within 3h at the Department of Food Science, 
division of Food Microbiology. All analyses and preparations were done in an anaerobic chamber 
(H2/C02/N2; 10:10:80, 21 °C, Hoekloos SHK050H , Rotterdam, The Netherlands), unless stated 
otherwise. Feces was diluted (10"') in 70 ml of a solution of buffered peptone water, tween 80 (1 
55 
Chapter 4 
g/L) and cysteine (0.5 g/L), then homogenized using an ultraturrax. Aliquots of 1 ml were diluted in 
reduced physiological peptone water in decimal steps. Of each of the dilutions 0.03 mL was plated 
in duplicate onto selective media. All media were kept at least 24h in the anaerobic chamber before 
use. 
Nutrient Agar (NA) was used to determine total aerobes (Oxoid CM 3, Basingstoke, United 
Kingdom) with dilutions of 10"2 - 10'5. For Escherichia coli Eosine Methylene Blue Agar (EMB, 
Oxoid CM 69, Basingstoke United Kingdom) was used with dilutions of 10"2 - 10s. Total anaerobes 
were counted on Fecal Reinforced Clostridial Agar (FRCA), which consisted of Reinforced 
Clostridial Medium (Oxoid CM 149, Basingstoke, United Kingdom) 38 g/L, Hemine solution 
(Sigma H2250, 50 mg/lOOmL, Sigma, St Louis, USA) 1%, Vitamin Kl solution (0.5% in 95% 
ethanol, Bufa Pharmaceuticals, Uitgeest, The Netherlands) 0.02%, Agar (Oxoid L13, Basingstoke, 
United Kingdom) 18 g/L, and fecal extract 100 ml. Fecal extract was prepared by mixing equal 
volumes of swine feces and Buffered Peptone Water (Oxoid CM 509, Basingstoke, United 
Kingdom) to which cysteine.HCl (1 g/L) and Tween 80 (10 g/L, Sigma P1754) were added. The 
mixture was homogenized and sterilized. Dilutions of 10"6 - 10"8 were used. Sulfite reducing 
Clostridia (mainly Clostridium perfringens) were counted on Perfringens Agar Base and supplement 
(CSA, Oxoid CM 587, SR 47 and SR 88, Basingstoke, United Kingdom) using dilutions of 10"3 -
10"7. For lactobaccili, LAMVAB was used (Hartemink et al, 1997) with dilutions of 10"2 - 10"7. 
Bifidobacteria were counted on Raffinose Bifidobacterium Agar (RB) in dilutions of 10"4 - 10"7 
(Hartemink et al, 1996). All dilutions were plated in duplicate. 
Plates of 6 cm diameter (Greiner, Kremsmunster, Austria) were used. All plates were 
incubated at 37 °C for 1-4 days. NA and EMB were incubated aerobically, all other media were 
incubated anaerobically. After incubation, colonies were counted according to colony morphology. 
Counts from duplicate plates were averaged. Media and incubation conditions were controlled using 
growth of selected test bacteria on each batch of medium. Anaerobic conditions were controlled 
using anaerobic indicator strips. All visible colony morphologies were tested microscopically to 
determine the selectivity of the media. 
Statistical analyses 
The average values for each person of both run-in and intervention periods were calculated and used 
for the determination of the differences between intervention and run-in diets. Differences were 
checked for normality by visual inspection of the normal probability plots (univariate procedure; 
SAS Institute Inc, Cary, NC). Bacterial counts were logarithmized to fit a normal distribution. The 
significance of the differences between the interventions was assessed by analysis of variance 
without interactions by using a model with subject (general linear models procedure). Adding start-
group to this model did not contribute to the significance; thus, there were no significant effects of 
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time. 
If there was a significant difference between treatments (P < 0.05), group means were 
compared by using the Dunnett test. This method encompasses a downward adjustment of the 
significance limit for multiple testing. 
Our strategy for controlling a type I error was based on our main outcome variable: 
bifidobacterial counts. A pilot experiment was performed prior to the study to assess the within-
subject variation of bacterial counts, which was 5% for bifidobacteria (data not shown). The present 
study was designed to detect a 7% increase in bifidobacterial counts after correction for the placebo-
treatment, which is about half the effect observed by Bouhnik et al (1997). We used data from 
literature and former studies at our department to estimate the variances for the other variables and 
used these to predict detectable responses to transgalacto-oligosaccharides for a given probability 
(Snedecor & Cochran, 1989). 
The statistical analysis package SAS, version 6.09 (Statistical Analysis Systems Institute, 
Inc., Cary, NC, USA) was used to perform the statistical analyses. 
Results 
Characteristics of subjects who completed the study are given in table 1. One female subject 
withdrew in the first week of the experiment because of personal reasons; data from this subject 
were excluded from analyses. All other subjects completed the study successfully. Some volunteers 
in the low-TOS and high-TOS groups had flatulence. There were no reports of problems with the 
palatability of the diets or the juices. 
Table 1. 
Population characteristics' 
Placebo group 
(n=13) 
Low-TOS group 
(n=13) 
High-TOS group 
(n=14) 
Sex (male/female) 
Age (y) 
Weight (kg) 
Length (m) 
Body Mass Index (kg/m2) 
7/6 
37.8 ± 17.6 
72.9 ± 10.5 
1.79 ± 0.09 
22.7 ± 2.6 
7/6 
36.5 ± 17.6 
71.0 ± 7.5 
1.75 ± 0.09 
23.4 ± 3.1 
8/6 
42.9 ± 14.8 
71.3 ± 10.6 
1.76 ± 0.12 
23.0 ± 2.1 
Mean ± SD. 
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The mean daily intakes of energy and the composition of the diets as determined by chemical 
analyses of duplicate diets and juices plus calculated contribution of free-choice items are given in 
table 2. 
Table 2. 
Daily dietary intake during the study1 
Placebo group Low-TOS2 group High-TOS2 group 
(n=13) (n=13) (n=14) 
Energy (MJ) 
Protein (% of energy) 
Fat (% of energy) 
Carbohydrates (% of energy) 
Alcohol (% of energy) 
Dietary fiber (g/MJ) 
Transgalacto-oligosaccharides (g) 
11.0 ±0.4 
16.2 + 0.1 
37.5 + 0.3 
44.3 + 0.6 
2.1 ± 0.7 
1.77 + 0.02 
0 
10.5 ± 0.4 
16.1 + 0.1 
37.3 + 0.1 
45.3 + 0.5 
1.3 ± 0.5 
1.74 + 0.02 
8.5 
11.0 + 0.5 
15.9 + 0.1 
36.9 ± 0.3 
45.7 ± 0.4 
1.5 ± 0.5 
1.76 ± 0.01 
14.4 
1
 Mean ± SEM per day. 
2
 TOS, transgalacto-oligosaccharides. 
Energy supplied by the free-choice items did not differ between the dietary regimes and accounted 
for 11.2% of total energy, with a range of 7.7% to 14.4%. There was no significant difference 
between run-in and intervention or between treatments in the intake of protein, carbohydrates, fat 
and fiber. The low-TOS diet contained a mean of 8.5 g transgalacto-oligosaccharides per day, the 
high-TOS diet contained 14.4 g transgalacto-oligosaccharides per (table 2). 
Breath hydrogen 
The individual changes in breath hydrogen concentration between intervention and run-in period are 
given in figure 1. The mean change was significantly higher (P < 0.01) in the high-TOS group than 
in de placebo group (95% CI: 1.8, 11.2 ppm). There were no differences between low-TOS and 
placebo. 
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Figure 1. Individual changes in breath hydrogen concentration on a placebo diet, a diet with 8.5 g of 
transgalacto-oligosaccharides (low-TOS) or a diet with 14.4 g of transgalacto-oligosaccharides per 
day (high-TOS). Breath samples were taken twice at the end of the run-in period and at the end of 
the intervention period. 
Bowel habit and stool composition 
Data on bowel habit, fecal weight, fecal nitrogen density and fecal pH are given in table 3. There 
was no fecal excretion of transgalacto-oligosaccharides on any of the interventions. The 
transgalacto-oligosaccharides did not significantly affect reported stool frequency, percentage of 
fecal dry matter, fecal weight or fecal pH. There was a significant increase of the fecal nitrogen 
density in the high-TOS group after correcting for placebo (95% CI; 0.04, 0.62). On low-TOS the 
increase was not statistically significant after correcting for the change in the placebo group (95% 
CI;-0.14, 0.46). 
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Chapter 4 
Short-chain fatty acids and bile acids in fecal water 
Total short-chain fatty acid concentration in fecal water did not differ between the three 
interventions (table 4). The pH of fecal water and the concentrations of acetate, propionate, butyrate 
and the sum of iso-butyrate, valerate, iso-valerate and caproate were also not affected by the 
transgalacto-oligosaccharides. The molar ratio of acetate:propionate:butyrate was approximately 
6:2:1 in all intervention groups. The total excretion of short-chain fatty acids per day was 
approximately 13 mmol/d. There were no differences in the excretion of short-chain fatty acids 
between the interventions. 
Total concentrations of bile acids in fecal water decreased in all intervention groups, but 
there were no differences between groups (table 6). The ratio of hydrophobic (mono+dihydroxy) to 
hydrophilic (keto+trihydroxy) bile acids was not affected by the interventions. Secondary bile acids 
comprised about 85% of total bile acids in all intervention groups. (iso)Deoxycholic acid was the 
most abundant bile acid. The total excretion of bile acids was approximately 70 umol/d, there were 
no differences in the excretion of bile acids between the interventions. 
Ammonia, indoles and skatoles in feces 
The fecal concentrations of ammonia, indoles and skatoles (table 5) were not affected by the 
transgalacto-oligosaccharides. The excretion of ammonia was approximately 85 mg/d, and did not 
differ between interventions. The excretion of indoles was 3 mg/d and of skatoles 1.3 mg/d, there 
were no differences between the interventions. 
The intestinal microflora 
Temperature of all samples for bacteriological analyses was checked. Mean temperature was 32.2 
°C. The temperature of four samples was somewhat below 29.2 °C (= mean - 2 *SD). These were 
all very small samples that probably cooled down more quickly. None of the samples was excluded 
from analyses because of a low temperature. Counts of fecal bacteria were not affected by the 
interventions. There was an increase in the amount of bifidobacteria in the placebo group (P<0.025), 
the low-TOS group (P<0.05) and the high-TOS group (P<0.05). The differences between these 
changes were not statistically significant (table 7). Figure 2 shows the mean changes in fecal 
bacterial counts with their 95% confidence intervals on the three intervention diets. The ratio of 
bifidobacteria to the total amount of anaerobic bacteria was approximately 10 and was not affected 
by the interventions. 
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Chapter 4 
Table 7. 
Fecal bacterial counts (log10 CFU/ g)1 
Placebo group Low-TOS2 group High-TOS group 
(n=13) (n=13) (n=14) 
Total anaerobes (log10 CFU/ g) 
Run-in 
Intervention 
Bifidobacteria (log10 CFU/ g) 
Run-in 
Intervention 
Lactobacilli (log10 CFU/ g) 
Run-in 
Intervention 
Clostridia (logI0 CFU/g) 
Run-in 
Intervention 
Total aerobes (log10 CFU/ g) 
Run-in 
Intervention 
E-coli(log10CFU/g) 
Run-in 
Intervention 
10.5 ± 0.1 
10.6 ±0.1 
9.4 ± 0.1 
9.8 ± 0.1 
5.0 ± 0.5 
5.0 ± 0.7 
7.9 ± 0.2 
8.1 ± 0.2 
7.5 ± 0.2 
7.6 ± 0.2 
7.1 ± 0.2 
7.1 ± 0.2 
10.4 ±0.1 
10.6 ± 0.1 
9.4 ± 0.1 
9.7 ± 0.1 
5.0 ± 0.5 
5.7 ± 0.7 
8.0 ± 0.1 
8.2 ± 0.1 
7.5 ± 0.2 
7.3 ± 0.2 
6.5 ± 0.6 
6.4 ±0.4 
10.4 ± 0.1 
10.6 ± 0.1 
9.2 ± 0.1 
9.6 ± 0.1 
5.9 ± 0.5 
6.5 ± 0.7 
8.0 ± 0.1 
7.9 ± 0.1 
7.5 ± 0.2 
7.3 ± 0.1 
6.2 ± 0.6 
6.7 ± 0.2 
' Mean ± SEM; CFU, colony forming units. 
2
 TOS, transgalacto-oligosaccharides. 
Discussion 
Our findings show that transgalacto-oligosaccharides, although fully fermented in the large 
intestine, do not beneficially change the composition or activity of the intestinal microflora. To our 
knowledge, this is the first placebo controlled feeding trial of transgalacto-oligosaccharide 
fermentation in humans. 
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Figure 2. Changes in fecal bacterial counts (mean and 95% CI) on a placebo diet, a diet with 8.5 g 
of transgalacto-oligosaccharides (low-TOS) or a diet with 14.4 g of transgalacto-oligosaccharides 
per day (high-TOS). 
Dietary intake, compliance to the treatment, fecal sampling and statistical power 
We believe that the lack of effect in our study on the main outcome variables related to composition 
and activity of the intestinal microflora can not be explained by differences in dietary intake, non-
compliance of the volunteers, inappropriate sampling and analysis of feces or by an insufficient 
statistical power of the experiment. 
Our study was a completely controlled feeding trial in which all volunteers consumed a diet 
that was similar in nutrient composition. The energy intake was adjusted in order to maintain stable 
body weights which was warranted by body weight measurements three times weekly. The values 
for the analyzed duplicate portions were combined with the calculations based on the reported free-
choice items. This allowed us to compute the energy and nutrient intakes of the volunteers during 
both run-in and intervention periods. There were no differences between the mean run-in and 
intervention diets for energy, macronutrients and dietary fiber, except for the amount of 
oligosaccharides in the diet. Total energy intake and the contribution of fat, protein and 
carbohydrates was similar for the intervention groups. We conclude that differences in dietary 
intake were negligible in our study and could not have affected the outcome. 
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The oligosaccharides in our study were dissolved in fruit juices. All diet items were color coded and 
the volunteers were blinded to their intervention group and to the vehicle of the oligosaccharides. 
There were no clear taste differences between the juices and none of the volunteers noticed anything 
unusual about them. The juices were divided over 3 portions of which one was taken together with 
the hot meal at our department. The other 2 portions were packed in sealed plastic bottles and 
consumed at home. Compliance as judged by the bottles that were emptied was near 100%. In an 
anonymous evaluation form we asked the volunteers about their compliance to the diet and it 
appeared to be extremely high for the juices. We therefore exclude the possibility that non-
compliance of the volunteers affected the results. Moreover, consumption of the TOS supplements 
was confirmed by the increased reported flatulence in the high-TOS group. 
When measuring the composition of the intestinal microflora, the handling and storing of 
fecal samples is of special importance (Bollongue, 1997; Haffejee, 1990). In a pilot study (Alles, 
1997a) we found out that storing and freezing the fecal samples in a glycerol broth as described by 
Crowther et al (1971) decreased the bacterial counts of both bacteroides and e.coli, and increased 
the amount of clostridial counts. We therefore tried to minimize exposure to oxygen and avoid 
freezing and storing of the samples. Volunteers were informed about the importance of a quick 
handling of their fecal samples. Within 5 min after defecation, fecal samples were transported into 
an anaerobic cabinet. Freshness of the samples was checked by measuring the temperature. Control 
strains grew well on all media batches, indicating that the media were not inhibitory. No oxygen 
leaks were detected. Bifidobacterial counts were in accordance with other fecal flora studies 
(Buddington et al, 1996; Ito et al, 1993a; Ito et al, 1990; Guerin-Danan et al, 1998; Gibson et al, 
1995a; Bouhnik et al, 1997). We are convinced that the fecal sampling in our study for the bacterial 
analyses was done carefully and could not have affected the results in any negative way. 
The study protocol was designed to detect a 7% increase in bifidobacterial counts by 
consumption of transgalacto-oligosaccharides as compared to placebo. This a-priori power 
calculation was based on a 5% within-subject variation. The variance in the present study was 
somewhat lower (4.8%), probably because of the controlled diet. It provided an 80% chance of 
detecting any 6.0% increase in the amount of bifidobacteria, after correction for placebo. We 
conclude from this a-posteriori power analysis that the actual effect of transgalacto-oligosaccharides 
on bifidobacteria is probably smaller than 6.0%. 
For most other end point variables, we were able to detect effects of 20% or smaller 
(range 2.8% to 18.8%) with 80% confidence. The within subject variation of fecal lactobacilli and 
bile acids was large (25 and 50%), as we had anticipated based on previous studies (Heijnen et al, 
1998). We did not have data on the variation in indoles and skatoles prior to the experiment, it 
appeared to be high (30 and 40%). For lactobacilli, bile acids, indoles and skatoles, a treatment 
induced effect of 30-60% was detectable with the present study design. The detectable effects in our 
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study were largely as we had anticipated and we therefore exclude the possibility that an insufficient 
power influenced our main outcomes. 
Apparent fermentability and gaseous response 
No transgalacto-oligomers were recovered from any of the fecal samples. As the oligosaccharides 
are acid-stable and not hydrolyzed by human intestinal enzymes (Burvall et al, 1980), it is likely 
that all transgalacto-oligosaccharides in our study were fermented by bacteria in the colon. To our 
knowledge, this is the first study showing such complete fermentation of transgalacto-
oligosaccharides through determination of the oligomers in the feces. 
Bacterial degradation of TOS was reflected in the production of hydrogen. In the highest 
TOS-group, the hydrogen concentration was increased by 138 %, while there was no increase in the 
placebo group. In the low-TOS group, there was no difference in hydrogen concentration with 
placebo (95% CI: -7.5, 5.5 ppm). Other dietary fibers might have masked the effect in the low-TOS 
group. We excluded hydrogen responders to lactose from our study, but we did not check for non-
hydrogen producers. Possible non-producers might have decreased the effect of TOS on mean 
hydrogen concentration. 
A hydrogen response to TOS was found before in both rats (Djouzi & Andrieux, 1997; 
Meslin et al, 1993) and humans (Tanaka et al, 1983). Bouhnik et al (1997) compared hydrogen 
excretion in humans after 1 d of TOS consumption (10 g/d) to excretion after 7, 14 and 21 days. 
They observed a lower hydrogen response in the course of the study, possibly due to adaptation of 
the microflora to the substrate. 
Bowel habits and stool composition 
We did not observe any effects of TOS on reported frequency of defecation, daily fecal weight, or 
fecal dry matter. We did show a significant effect on the nitrogen density of the fecal dry matter of 
the high TOS treatment. 
We hypothesized that TOS would increase bacterial proliferation and thereby bacterial mass. 
As fecal bacteria contribute considerably to fecal weight (Stephen & Cummings, 1980; Hill, 1995), 
we expected to find an increase in total fecal weight, with a shift to a more watery constitution as 
bacteria are 80% water (Stephen & Cummings, 1980). We expected to find an increase in the 
frequency of defecation due to the laxative effects of an increased fecal mass. Although studies with 
other types of non-digestible oligosaccharides show an increase in stool weight (Alles et al, 19976; 
Gibson et al, 1995a; Mortensen, 1992), or defecation frequency (Gibson et al, 1995a), our study 
and other TOS-studies (Ito et al, 1990; Bouhnik et al, 1997) did not show such effects. We did find 
a significant increase of 6.5% in the nitrogen density of the fecal dry matter on the high-TOS 
treatment, which increased the nitrogen excretion by 0.12 g/d after correction for placebo. This 
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increase is likely to be due to an increase in the bacterial mass (Gibson et al, 1995a; Stephen & 
Cummings, 1980; Levrat et al, 1993; Younes et al, 1995). The additional 0.12 g of N excreted is 
equivalent to approximately 1.9 g of bacterial solids (Stanier et al, 1979) and 9.5 g of wet stool 
(Stephen & Cummings, 1980). The subsequent theoretical changes in fecal wet weight and fecal dry 
matter due to the increased bacterial mass were probably too small to detect. 
Short-chain fatty acids and bile acids in fecal water 
Transgalacto-oligosaccharides did not significantly affect fecal pH or the concentrations of short-
chain fatty acids or bile acids in fecal water. 
Our data do not allow firm conclusions about the effect of transgalacto-oligosaccharides on 
the production of short-chain fatty acids in fecal water or on the pH of the colon content. When 
hydrogen is produced, most bacteria simultaneously produce short-chain fatty acids (Cummings & 
MacFarlane, 1991). MacFarlane et al (MacFarlane et al, 1992), in an autopsy study of victims of 
sudden death, found high amounts of short-chain fatty acids in the proximal colon and lower 
amounts towards the end of the gastrointestinal tract. They attributed this to rapid absorption of 
these acids by the colonic mucosa. As oligosaccharides are rapidly fermented, possibly to a large 
extent in the proximal colon, fecal pH and the fecal concentration of short-chain fatty acids are not 
necessarily good indicators for saccharolytic activity. Other researchers also failed to show any 
effects of fermentable carbohydrates on short-chain fatty acids or fecal pH (Philips et al, 1995; 
Heijnen et al, 1998; Alles et al, 1996; Alles et al, 19976; Munster et al, 19946). Of the total amount 
of short-chain fatty acids, 62% was acetate, 19% was propionate and 10% was butyrate. These 
proportions are in the same range as reported before (Munster et al, 19946; Gibson et al, 1995a; 
Cummings, 1981; Heijnen et al, 1998), and did not differ among treatments. 
We were unable to show any effects of transgalacto-oligosaccharides on the 
concentration of bile acids in fecal water. We hypothesized that acidification of the colon content, as 
a result of the fermentation of oligosaccharides, would lead to precipitation of the soluble 
deconjugated bile acids (Fini & Roda, 1987; Bruce, 1987; Munster & Nagengast, 1993) and to a 
suppression of the bacterial conversion of primary to secondary bile acids (Christl et al, 1997; 
Munster & Nagengast, 1993). This would lead to lower concentrations of bile acids and a smaller 
ratio of hydrophobic to hydrophilic bile acids in the aqueous phase of feces, resulting in a bile acid 
profile with smaller cytolytic capacity (Lapre et al, 1993). On a low-fiber diet, the production of 
acids by fermentation processes is probably low. Increasing our low-fiber diet with fermentable 
transgalacto-oligosaccharides might not have been effective in reaching the acidification necessary 
for the expected effects on bile acids. Due to the high within-subject variation, only large effects on 
the concentration of bile acids were detectable with our study-design, which allowed us to show 
effects of 60% with 90% confidence and of 50% with 80% confidence. Although such effects have 
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been shown by others, using different dietary treatments (Munster et al, 1994ft; van Faassen et al, 
1996; Nagengast et al, 1988ft), we might have missed possible smaller effects in the present study. 
Ammonia, indoles and skatoles in feces 
Transgalacto-oligosaccharides did not lower fecal concentrations of the protein degradation 
products ammonia, indoles and skatoles. 
We hypothesized that transgalacto-oligosaccharides would decrease protein fermentation 
products by two mechanisms. Firstly, we expected to find a depression of protein fermentation by 
providing the bacteria with an easy carbohydrate source. Both substrate competition and a low pH 
are thought to decrease the use of endogenous and dietary proteins as an energy source for bacteria 
(Mortensen et al, 1990; Alles et al, 1997ft). Also, when transgalacto-oligosaccharides are used as an 
energy substrate by the bacteria, nitrogen sources are required for the subsequent increase in 
bacterial growth. Use of ammonia as a source of bacterial nitrogen, leads to decreased 
concentrations of fecal ammonia and an increase of bacterial nitrogen (Birkett et al, 1996; 
Mortensen et al, 1990; Levrat et al, 1993). 
We did not observe a decrease in the fecal concentrations of the protein degradation 
products ammonia, indoles and skatoles. We also did not observe a decrease in the concentration of 
isobutyrate, valerate, isovalerate and caproate, which are short-chain fatty acids that originate from 
bacterial breakdown of amino acids (Rasmussen et al, 1988; MacFarlane & MacFarlane, 1993). Ito 
et al (1993a, 1993ft) and Djouzi et al (Djouzi & Andrieux, 1997) showed a decrease in one or more 
of the above mentioned variables. Ito e.g. showed a 37.2% decrease in the concentration of indoles 
by supplementing the diet of Japanese men with 2.5 g of transgalacto-oligosaccharides per day for 3 
weeks (Ito et al, 1993a). The power of detecting such an effect in our study was 80%. 
We chose for a background diet with a relative high protein content (16%) in order to 
increase protein fermentation of dietary proteins (Gibson et al, 1976). We hereby expected to 
increase the chance of showing inhibiting effects of transgalacto-oligosaccharides on this 
fermentation. Levrat et al (Levrat et al, 1993) studied the effects of the fermentable carbohydrate 
inulin in rats fed a high versus a moderate protein diet. They showed that use of ammonia as a 
source of bacterial growth was increased on inulin, but more evident when the dietary protein level 
was moderate. In high protein diets, uremia and flux of urea from plasma to colon is high and an 
important determinant of fecal concentrations of ammonia (Levrat et al, 1993; Younes et al, 1995). 
We conclude that transgalacto-oligosaccharides have no significant effects on protein fermentation 
when supplemented to a high protein background diet. 
Intestinal microflora 
We did not observe any effects of transgalacto-oligosaccharides on the composition of the intestinal 
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microflora when tested in a controlled feeding trial against a placebo treatment. 
It was striking that bifidobacterial counts increased by 4% in the course of the study, 
independently of the treatment. The differences between the increases on placebo and transgalacto-
oligosaccharides were not statistically significant. Without the placebo group, the conclusion would 
have been that transgalacto-oligosaccharides selectively increase bifidobacteria in the gut. We can 
not explain the increase of bifidobacteria in all groups. There were no differences in the background 
diet or in the handling and analyzing of the fecal samples. There were no other bacteria that 
increased during the study. Moreover, test bacteria were analyzed every week and showed no 
tendency to rise during the study. We hypothesize that there might have been an adaptation of 
bifidobacteria to the background diet (high-protein, low-fiber). It is known from animal studies that 
sudden extreme changes in diet can have profound effects on the composition of the intestinal 
microflora. The flora will adapt gradually to the changes in substrate supply (Koopman, 1984). 
There was a non-significant rise in lactobacilli on both low-TOS (of 14%) and high-TOS (of 
10%), which we were unable to detect because of the large variation. 
Other researchers have shown that certain non-digestible oligosaccharides selectively 
stimulate the growth of bifidobacteria in the large intestine. Often linear study designs were used 
with measurements before and after the treatment (Ito et al, 1993a; Bouhnik et al, 1997; Gibson et 
al, 1995a; Buddington et al, 1996). Our results indicate the importance of a placebo treatment to 
exclude possible time, placebo and unknown factors. 
Our volunteers were healthy volunteers, not especially selected for having low 
bifidobacterial counts. In this population, using a high-protein and low-fiber diet, we were unable to 
show any effects of transgalacto-oligosaccharides on the composition of the intestinal flora. It might 
be difficult to get diet-induced changes when there is a stable and healthy balance in the microfloral 
population. 
Conclusions 
We conclude that transgalacto-oligosaccharides, supplemented to a relative decadent diet, are 
completely fermented in the colon of healthy individuals, but do not beneficially affect the 
composition of the intestinal microflora nor the putative risk markers of colon cancer. We believe 
that the lack of effect in our study on the main outcome variables related to composition and activity 
of the intestinal microflora could not be explained by differences in dietary intake, non-compliance 
of the volunteers, inappropriate sampling of feces or by an insufficient statistical power of the 
experiment. It remains possible that transgalacto-oligosaccharides have effects in other study-
populations such as people with low bifidobacterial counts, or when tested against another 
background diet. 
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Fructo-oligosaccharides and transgalacto-
oligosaccharides affect the bacterial glycosidase activity 
in human subjects 
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Abstract 
Non-digestible oligosaccharides have been claimed to benefit the health of the colon by affecting 
composition and activity of the intestinal microflora. We performed two human trials to test 
whether fructo-oligosaccharides (FOS-study) and transgalacto-oligosaccharides (TOS-study) would 
change the bacterial glycosidase activity in the colon. In the FOS-study we investigated 
fermentation of fructo-oligosaccharides in 24 healthy men by using a placebo-controlled crossover 
design (with glucose as the placebo). Fructo-oligosaccharides significantly decreased a-L-
arabinofuranosidase activity by 35%. The TOS-study was a controlled feeding trial in which the 
effects of transgalacto-oligosaccharides were tested in 25 healthy volunteers receiving either 
transgalacto-oligosaccharides or placebo. Transgalacto-oligosaccharides significantly increased the 
activity of 13-galactosidase by 123%. Neither fructo-oligosaccharides nor transgalacto-
oligosaccharides affected the activities of 6-glucosidase or 6-glucuronidase, which are enzymes 
involved in the generation of toxic compounds. We conclude that non-digestible oligosaccharides 
affect glycolytic activity of human intestinal bacteria in a substrate specific manner. 
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Introduction 
Non-digestible oligosaccharides naturally occur in various edible food plants (Loo et al, 1995) and 
in human breast milk (Carlson, 1985; Coppa et al, 1993; Gronberg et al, 1989). As they are not 
hydrolyzed by the enzymes in the human small intestine, they reach the colon intact. Bacterial 
fermentation of oligosaccharides in the colon has been claimed to benefit its health by selectively 
stimulating the growth of bifidobacteria and by decreasing colon cancer risk markers (Ito et al, 
1990; Bouhnik et al, 1997; Gibson et al, 1995a; Buddington et al, 1996; Bouhnik et al, 19966). 
Gut bacteria degrade non-digestible carbohydrates by using a wide range of depolymerizing 
enzymes. Polysaccharidase and glycosidase activities are found extracellularly as well as associated 
with bacterial cells (MacFarlane et al, 1991; Cummings & MacFarlane, 1991). By inducing these 
enzymes, dietary components may affect the metabolic activity of the microflora. Several studies 
were done to measure the end-products of bacterial breakdown of non-digestible oligosaccharides 
and often no effects were found on their fecal excretion (Alles et al, 1996; Alles et al, \991b; 
Gibson et al, 1995a). This might be due to a rapid absorption and utilization of fermentation 
products by the colonic mucosa (Hoverstad et al, 1982; Cummings et al, 1987). MacFarlane et al 
(1991) measured the glycosidase activities in different regions of the human large intestine and 
conclude that activities were found throughout the large intestine without significant regional 
differences. Therefore, the activity of glycolytic enzymes in feces might be a more relevant measure 
to study the metabolic activity of the intestinal microflora, then fecal end-products of bacterial 
fermentation. Little is known about the glycolytic responses to consumption of non-digestible 
oligosaccharides by humans, but in a rat experiment by Djouzi et al (1997) it was found that there 
are profound differences between oligosaccharides. 
We studied bacterial glycosidase activity induced by consumption of non-digestible 
oligosaccharides compared with digestible carbohydrates in two human trials. The first experiment 
was a free-living study done with fructo-oligosaccharides, which are short-chain fructans. The 
second experiment was a controlled feeding trial, using transgalacto-oligosaccharides, which are 
produced from lactose by enzymatic transgalactosylation. This work is an extension of previous 
studies that describes the fate of fructo-oligosaccharides in the human intestine (Chapter 2) and the 
effects of transgalacto-oligosaccharides on microbial composition and colon cancer risk markers 
(Chapter 4). 
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Methods 
Fructo-oligosaccharides study 
Experimental methods are described in detail in Chapter 2. Briefly, twenty-four healthy men aged 
19-28 years participated in a single-blind crossover trial with supplement periods of 7 d and a 7d 
wash-out period. The supplements where consumed in random order and consisted of either 15 g of 
fructo-oligosaccharides (Raftilose P95®, ORAFTI, Tienen, Belgium) or 4 g of glucose (Cerestar Pur 
01934; Cerestar Benelux BV, Sas van Gent, The Netherlands). Fructo-oligosaccharides had a degree 
of polymerization of 2-7 monosaccharide units. 
At the end of each supplement period volunteers came to the Department twice to defecate. 
Within 15 min after defecation the feces were weighed and immediately deep-frozen on dry ice to 
stop fermentation, then stored at -20°C. 
Transgalacto-oligosaccharides study 
This investigation formed part of a larger study, details of the experimental design and results on 
composition of the intestinal microflora and colon cancer risk markers are presented in Chapter 4. 
The experiment was preceded by a screening procedure, comprising a healthy questionnaire, blood 
and urine analyses, a transgalacto-oligosaccharides tolerance test and a lactose breath test. Forty-one 
volunteers (19 women and 22 men) entered a strictly controlled single-blind parallel experiment. 
The study was divided into two consecutive 3-week periods during which each participant 
consumed a run-in diet in the first 3 weeks followed by a 3-week intervention diet which differed 
only in the amount of transgalacto-oligosaccharides: 0 g/d (placebo) or 15 g/d (Elix'or®, Borculo 
Whey Products, Borculo, the Netherlands). Transgalacto-oligosaccharides were produced by 
transgalactosylation of lactose and had a degree of polymerization of 2-8 monosaccharide units. The 
diets consisted of conventional foods, and the nutrient composition of each diet was similar. 
Approximately 90% of energy intake was from supplied food, the remaining 10% was from 
products chosen by the subjects from a list of items. In the last week of both run-in and intervention 
period, volunteers came to the Department twice to defecate. Within 10 min after defecation the 
feces was deep-frozen on dry ice to stop fermentation, then stored at -20°C. In the last weekend of 
run-in and intervention periods, subjects collected all stools and stored them immediately on dry 
ice. 
Both studies were approved by the Medical Ethics Committee of the Division of Human 
Nutrition and Epidemiology. The protocol and aims of the study were fully explained to the 
volunteers, who gave their informed written consent. 
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Preparation of stool samples 
Samples were thawed overnight at 4 °C. Feces of a single person of one period were weighted and 
homogenized in a bowl and mixer. A portion was used for the preparation of the aqueous fraction of 
stool and centrifuged at 26000 g for 90 min at 4 °C (MSE, Scientific Instruments, Crawley, Sussex, 
UK). Fecal water was carefully removed and stored at -20°C until analysis of glycolytic enzymes. 
Bacterial glycolytic activities 
Glycosidases are enzymes which can cleave off single units of sugar residues from glycosylated 
compounds including the non-reducing site of oligomeric sugars. The p-nitrophenyl glycoside assay 
(pnp-assay) was used to measure the rate of release of p-nitrophenol from p-nitrophenylglycosides 
in fecal water. We tested the following bacterial glycosidase activities: a-L-arabinofuranosidase, oc-
glucosidase, P-glucosidase, a-galactosidase, (i-galactosidase, (^-glucuronidase, P-xylosidase, a-
fucosidase. The reaction mixture contained 25 ul substrate solution (0.1% w/v, Sigma, St-Louis MI, 
USA) and 15 ul of the diluted fecal water (1:11) in 75 ul phosphate buffer (50 mM, pH 6.5). 
Incubation was at 37 °C and the release of p-nitrophenol from pnp-glycosides was measured 
spectrophotometrically at 405 nm after addition of 125 ul of glycine (0.5 M glycine NaOH buffer, 
pH 9.0 + 2 mM EDTA). The activity was calculated using a molar extinction coefficient of 13700 
M"1 cm"1. Incubation time changed between substrates. Enzyme activities were expressed as units, 
one unit corresponds to the release of 1 umol glycoside min"1 under standard conditions. 
Absorbances exceeding 1 after correction for the blank, were diluted further and measured again. 
Statistical methods 
Differences were checked for normality by visual inspection of the normal probability plots. For 
the fructo-oligosaccharides study, paired t-tests were used to test the difference between placebo 
and fructo-oligosaccharides supplementation. For the transgalacto-oligosaccharides study, unpaired 
t-tests were used to test the differences between changes. Two-sided P-values less then 0.05 were 
considered significant. The statistical analysis package SAS, version 6.09 (Statistical Analysis 
Systems Institute, Inc.; Cary, NC, USA) was used to perform the statistical analyses. 
Results 
Fructo-oligosaccharides study 
All volunteers completed the study successfully, were apparently healthy and had normal body 
weight (BMI 21.7 (SD 1.9) kg/m2). In 4 fecal samples, there was too little fecal water extractable. 
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Compared with the placebo treatment, there was a significant decrease (of 34.8%) in the 
arabinofuranosidase activity on the fructo-oligosaccharides supplement. There was a non-significant 
increase in B-galactosidase activity of 45.3% (P = 0.0605) and a non-significant decrease in fi-
xylosidase of 18.8% (P = 0.075). There were no other changes in glycosidase activity (table 1). 
Transgalacto-oligosaccharides study 
One female subject withdrew in the first week of the experiment because of personal reasons; data 
from this subject were excluded from analyses. In four subjects, there was too little fecal water 
extractable from feces. All other subjects completed the study successfully. They were healthy and 
had normal body weight (BMI 22.8 (SD 2.3) kg/m2). 
Transgalacto-oligosaccharides significantly increased the activity of 13-galactosidase by 
122.8%, after correction for placebo. There were no other changes in glycosidase activity (table 2). 
Discussion 
We found that fructo-oligosaccharides and transgalacto-oligosaccharides, two non-digestible 
oligosaccharides, affect the glycolytic activity of human intestinal bacteria in a substrate specific 
manner, without increasing those enzymes that are involved in the production of toxic and 
carcinogenic metabolites. 
We measured the glycosidase activity aerobically in fecal water, which reflects the 
extracellular enzyme activity. As the feces was frozen before we prepared the fecal water, some 
intracellular enzymes might have been released due to lysis of bacteria. MacFarlane et al 
(MacFarlane et al, 1991) found that cell-bound activities are between 11 and 19 fold greater than 
those occurring extracellularly. The relative distribution of the enzymes however between 
extracellular and cell-bound enzymes did not differ much in their study. 
Both the decrease of arabinofuranosidase on fructo-oligosaccharides and the increase of 13-
galactosidase on transgalacto-oligosaccharides were not due to differences in the proportion of fecal 
wet weight. Correction for fecal wet weight did not change the results. 
The availability of substrates to gut bacteria leads to the induction of substrate specific hydrolyzing 
enzymes. Fructo-oligosaccharides can be hydrolyzed by 6-fructosidase and transgalacto-
oligosaccharides can be hydrolyzed by fi-galactosidase. We did not measure the activity of B-
fructosidase, as no pnp-substrates are available for this enzyme. However, Bouhnik et al (19966) 
described a method for measuring the (5-fructosidase activity using High Performance Anion 
Exchange Chromatography. They showed an increase in 13-fructosidase activity after consumption 
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of fructo-oligosaccharides. In the TOS-study, we showed an enhanced activity of B-galactosidase by 
specific substrate induction by transgalacto-oligosaccharides, which was not due to differences in 
fecal weight. This was also found by Djouzi et al (1997) in rats. 
Substrates can also affect the activity of non-specific glycolytic enzymes, due to either 
changes in microflora composition or shifts in the metabolic activity of individual species or strains 
(Djouzi & Andrieux, 1997; Buddington et al, 1996; Reddy et al, 1992). We observed a decreasing 
effect of fructo-oligosaccharides on the activity of a-L-arabinofuranosidase, which was also not due 
to differences in fecal weight. Arabinofuranosidase is the enzyme that degrades arabinosyl linkages 
from various hemicelluloses such as arabinans, (arabino)xylans, (arabino)galactans and arabinose-
substituted xyloglycans (Kaji, 1984). Fructo-oligosaccharides also increased the activity of B-
galactosidase and decreased the activity of B-xylosidase. Probably due to the small number of 
volunteers relative to the large variation in enzyme activities, these changes were not statistically 
significant. 
Changing the activity of glycolytic enzymes may affect human health. Some of the enzymes 
help to generate energy for the colon mucosa in the form of butyrate. Increasing the activity of B-
galactosidase allows further degradation of lactose that escapes digestion and of arabinogalactans, 
which are important non-starch polysaccharides. 
Other bacterial enzymes may have adverse effects in the colon. B-Glucuronidase is involved 
in the hydrolysis of glucuronide conjugates in the gut, which lead to the generation of toxic and 
carcinogenic metabolites (Rowland, 1988; Mallett & Rowland, 1987). The hydrolytic activity of B-
glucosidase is responsible for the generation of mutagenic aglycones (Mallett & Rowland, 1987). 
We and others (Djouzi & Andrieux, 1997; Bouhnik et al, 1996a; Kleessen et al, 1997; Bouhnik et 
al, 19966) did not show any effects of fructo-oligosaccharides or transgalacto-oligosaccharides on 
the activity of B-glycosidase and B-glucuronidase. Buddington et al (1996) showed a decrease of B-
glucuronidase on fructo-oligosaccharides but did not compare the effects with a placebo treatment 
and was thus unable to exclude possible time effects. 
This study shows that the glycolytic activity of human intestinal bacteria in feces can be 
used as a biomarker of colonic metabolic activity, in dietary interventions with non-digestible 
oligosaccharides. Although our study design was not ideally suited to test the differences between 
fructo-oligosaccharides and transgalacto-oligosaccharides, we showed that non-digestible 
oligosaccharides affect the glycosidase activity in a substrate specific manner. Both substrates did 
not affect those enzymes that generate toxic and carcinogenic metabolites. 
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Consumption of fructo-oligosaccharides does not 
favorably affect blood glucose and serum lipids in non-
insulin dependent diabetic patients 
Martine S. Alles, Nicole M. de Roos, J. Card Bakx, Eloy van de Lisdonk, Peter L. Zock, Joseph 
G.A.J. Hautvast. The American Journal of Clinical Nutrition, in press. 
Abstract 
Fructo-oligosaccharides have been claimed to lower fasting glycemia and serum total cholesterol 
concentrations, possibly via effects of short-chain fatty acids from fermentation. We studied the 
effects of fructo-oligosaccharides on blood glucose, serum lipids and serum acetate in 20 non-
insulin dependent diabetic patients. In a randomized, single-blind crossover design, patients 
consumed either glucose as a placebo (4 g/d) or fructo-oligosaccharides (15 g/d) for 20 days each. 
Average daily intakes of energy, macronutrients and dietary fiber were similar on both treatments. 
Compliance, expressed as the proportion of supplements not returned, was near 100% during both 
treatments. Fructo-oligosaccharides did not significantly affect fasting concentrations of serum total 
cholesterol (95% CI; -0.07, 0.48 mmol/L), HDL cholesterol (95% CI; -0.04, 0.04 mmol/L), LDL 
cholesterol (95% CI; -0.06, 0.34 mmol/L), serum triacylglycerol (95% CI; -0.21, 0.44 mmol/L), 
serum free fatty acids (95% CI; -0.08, 0.04 mmol/L), serum acetate (95% CI; -0.01, 0.01 mmol/L) 
or blood glucose (95% CI; -0.37, 0.40 mmol/L). We conclude that 20 days of dietary 
supplementation with fructo-oligosaccharides has no major effect on blood glucose, serum lipids or 
serum acetate in non-insulin dependent diabetic patients. This lack of effect was not due to changes 
in dietary intake, insufficient statistical power or non-compliance of the patients. 
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Introduction 
Fructo-oligosaccharides are non-digestible oligosaccharides that naturally occur in various edible 
food plants such as onions and leeks (Van Loo et al, 1995; Spiegel et al, 199'4). The recent use of 
fructo-oligosaccharides as a food ingredient has triggered much research on their possible health 
effects. As fructo-oligosaccharides are not hydrolyzed by enzymes in the human small intestine, 
they reach the colon intact. In a previous study we showed that fructo-oligosaccharides, added to the 
diet of young healthy subjects, are fully metabolized by the colonic microflora (Alles et al, 1996). 
End products of carbohydrate fermentation are gases, lactate and short-chain fatty acids, such as 
acetate, propionate and butyrate. Fermentation of fructo-oligosaccharides probably takes place in 
the proximal colon leading to a rapid increase in breath hydrogen after consumption (Alles et al, 
1996; Rumessen et al, 1990; Alles et al, 19976). The short-chain fatty acids that are produced 
during this fermentation are thought to be readily absorbed by the colonic mucosa (Pomare et al, 
1985; Cummings et al, 19876; Rombeau & Kripke, 1990). It is known that butyrate serves as a fuel 
for the mucosa, whereas acetate and propionate enter the portal blood and may influence systemic 
carbohydrate and lipid metabolism (Cummings et al, 19876). Because acetate and propionate have 
dissimilar effects on glycaemia (Akanji et al, 1989; Akanji & Hockaday, 1990; Thorburn et al, 
1993; Wolever et al, 1991; Carman et al, 1993; Boillot et al, 1995) and serum lipids (Wolever et al, 
1995; Wolever et al, 1991; Wolever et al, 1996; Kok et al,. 1996), the pattern of fermentation of 
fructo-oligosaccharides might be of importance when predicting their metabolic effects. 
Yamashita et al (1984) studied the systemic effects of adding 8 g of fructo-oligosaccharides 
to the daily diet of non-insulin dependent diabetics whose blood glucose and serum lipid levels were 
still uncontrolled. They found an 8% decrease in fasting blood glucose levels, a 6% decrease in total 
cholesterol and a 10% decrease in LDL cholesterol. Several rat experiments have been done since, 
all showing that fructo-oligosaccharides lower serum triacylglycerol, total-, LDL- and VLDL-
cholesterol (Fiordaliso et al, 1995; Levrat et al, 1994; Kok et al, 1996; Delzenne et al, 1993). Two 
recent intervention studies were done in healthy humans. A study by Luo et al (1996) showed that 
chronic consumption of 20 g of fructo-oligosaccharides daily only increased basal hepatic glucose 
production but had no effect on insulin-stimulated glucose metabolism or serum lipids. Pedersen et 
al (1997) studied the effect of inulin on blood lipids and did not find any changes in either total 
cholesterol, HDL cholesterol, LDL cholesterol or triacylglycerol. Thus the effects of fructo-
oligosaccharides on blood glucose and serum lipids are not yet clear. 
In the present study we investigated the effects of fructo-oligosaccharides in twenty non-
insulin dependent diabetic patients on serum acetate concentrations, fasting glycaemia, free fatty 
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acids, triacylglycerol, total, LDL and HDL cholesterol, in a 6-weeks placebo-controlled experiment 
using a cross-over design. 
Materials and methods 
Patients and experimental design 
We recruited patients that were diagnosed with non-insulin dependent diabetes using WHO 
diagnostic criteria (WHO Study Group, 1994), from 5 general practices in the environment of 
Nijmegen. All practices were connected to the Nijmegen Monitoring Project, the registration 
network of the Department of General Practice of the University of Nijmegen. Twenty non-insulin 
dependent diabetic patients (9 men and 11 postmenopausal women) were selected. All patients had 
previous measures of fasting blood glucose levels exceeding 6.5 mmol/L and fasting serum 
cholesterol levels exceeding 6 mmol/L. Participants had no history of gastrointestinal disease, and 
had not been treated with antibiotics or laxatives in the 3 months prior to the experiment. Patients 
were treated for their diabetes by dietary advice and 17 patients used oral blood glucose lowering 
medication. Patients were also treated for diabetes related co-morbidity and used e.g. 
antihypertensive agents (9 subjects) and lipid-lowering drugs (1 subject). 
The study protocol was approved by the Medical Ethics Committee of the Division of 
Human Nutrition and Epidemiology. The protocol and aims of the study were fully explained to the 
patients, who gave their informed written consent. After successfully completing the study, the 
patients received a small financial reward. 
A single-blinded placebo-controlled crossover design for 2x20 days was used; there was no 
wash-out period between the treatments. Each participant used each of two supplements in random 
order. Blood samples were collected at the end of each treatment period. Patients kept a diary in 
which they recorded time of supplement consumption, possible diseases or discomfort, medication 
used and deviations in eating, drinking or lifestyle behavior. Complaints of flatulence were rated on 
a 4-point Likert scale (none; mild; moderate; severe). 
Supplements and food intake 
Patients were instructed to maintain habitual eating, drinking and lifestyle behavior. They were 
asked not to eat probiotic dairy products which contain micro-organisms able to survive passage 
through the upper gastrointestinal tract, or to consume products containing large amounts of fructo-
oligosaccharides, such as onions and leeks. Subjects were given a list of these foods. 
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The patients recorded their habitual diet for two days in each treatment period. These food records 
were coded and the nutrient and energy intakes were calculated with use of the modified version of 
the 1993 release of The Netherlands Nutrient Data Bank (Anonymous, 1993a). 
On day 1 of the study, the patients were randomly assigned to daily treatment with 15 g of 
fructo-oligosaccharides (Raftilose P95®; ORAFTI, Tienen, Belgium) or 4 g of glucose as a placebo 
(Cerestar Pur 01934; Cerestar Benelux BV, Sas van Gent, The Netherlands). The supplements were 
aimed to be iso-energetic (» 70 kJ/d) (Roberfroid et al, 1993) and of equal sweetness (Franck-
Frippiat, 1995). Ten patients started out on fructo-oligosaccharides and 10 on placebo. Patients 
consumed the supplements in split dose; half of the supplement at breakfast and the other half at 
dinner. The supplements were mixed with yogurt. To prevent any gastrointestinal complaints when 
starting with the fructo-oligosaccharides without adaptation, the dose was gradually increased 
during the first three days with steps of 5 grams per day. 
Blood sampling and analyses 
Blood was taken by the practice assistants on days 1,18 and 21 (period 1) and days 39 and 42 
(period 2) after an overnight fast (12 h) and in the sitting position. 
For glucose measurements, capillary blood samples were taken from a finger. A drop of 
blood was placed on a test-strip and blood glucose was measured immediately with a blood glucose 
meter. The participating practices used different glucose meters, but standard procedures were used 
for each glucose meter and repeated measurements were done using the same equipment. All 
glucose meters were gauged before the experiment. 
For the lipid analyses, blood was obtained by venipuncture using a standardized protocol. 
After the blood samples had been allowed to clot (15-30 min), the tubes were put on ice and 
transported to the laboratory where serum was obtained by low-speed centrifugation (10 min, 1500 
g, 4°C; Sigma 4K10, Salm en Kipp BV, Breukelen, The Netherlands). Within 2 h after sampling 
serum was stored at -80°C until analyses. 
Lipids were analyzed enzymatically for total cholesterol (Siedel et al, 1983), HDL 
cholesterol (Warnick et al, 1982) and triacylglycerol (Fossati & Prencipe, 1982) on a Spectrum 
Analyzer (Abbott Laboratories, Chicago, USA). The coefficient of variation within runs was 1.0% 
for total cholesterol, 1.4% for HDL cholesterol and 0.5% for triacylglycerol. The mean bias with 
regard to the target values from serum pools provided by the Centers for Disease Control and 
Prevention, Atlanta, was -1.4% for total cholesterol, 0.8% for HDL cholesterol, and 9.7% for 
triacylglycerol. LDL cholesterol was calculated by using the equation of Friedewald et al 
(Friedewald et al, 1972). 
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Free fatty acids in serum were measured enzymatically (Cat. no. 1383 175, Boehringer Mannheim 
GmbH, Mannheim, Germany). The mean recovery of the standard (palmitic acid) was 69% and a 
correction factor of 1.44 was used for all data. 
Serum acetate was measured after deproteinizing the samples. Perchloric acid (0.5 ml, 1 M) was 
added to the serum samples (0.5 mL). After centrifugation (15 min, 1500 x g) potassiumhydroxide 
(45 ml, 4M) was added to the supernatant (0.6 mL) and after a second centrifugation step (10 min, 
1500 g), acetate was measured enzymatically in the supernatant (Cat. no. 148 261, Boehringer 
Mannheim, Mannheim, Germany). Values were corrected for volumes, for the specific gravity and 
for the liquid fraction of serum. The mean recovery of the standard was 100%. 
For all blood variables, samples from one particular patient were analyzed in one run. 
Table 1. 
Patient characteristics and baseline blood values' 
Males Females 
(n = 9) (« = H) 
Characteristics 
Age (y) 
Height (m) 
Weight (kg) 
Body mass index (kg/m^) 
Baseline blood values 
Total serum cholesterol (mmol/L) 
Serum triacylglycerol (mmol/L) 
Blood glucose (mmol/L) 
1 Values are expressed as mean ± SD. 
Statistical analyses 
For statistical analyses, the values of two blood samples per person, taken at the end of each period, 
were averaged. Complaints of flatulence were averaged over the last two weeks of each supplement 
period. 
The differences between the two treatments were normally distributed as judged by visual 
inspection of the normal probability plots (SAS, univariate procedure). We used an ANOVA model 
including patient and treatment. Adding period to this model did not contribute to the significance, 
indicating that there were no significant effects of time or sequence of the treatments (SAS, general 
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56 
1.76 
91.1 
29.4 
5.61 
2.66 
8.83 
± 
± 
± 
± 
± 
± 
± 
5.2 
0.07 
14.4 
4.22 
1.34 
1.46 
2.30 
62 
1.65 
74.3 
27.4 
6.26 
2.95 
8.06 
± 
± 
± 
± 
± 
± 
± 
4.1 
0.07 
9.05 
2.72 
0.89 
1.53 
1.75 
Chapter 6 
linear models procedure). We then used paired f-tests to test for differences between the placebo and 
fructo-oligosaccharide treatment. P-values of less than 0.05 were considered significant. The 
variation (sd) in the effect was calculated and used to estimate the detectable effect of the treatment 
with a given probability (Snedecor & Cochran, 1989). 
The statistical analysis package SAS, version 6.09 (Statistical Analysis Systems Institute, 
Inc., Cary, NC, USA) was used to perform the statistical analyses. 
Results 
Characteristics of the study population are given in table 1. Cholesterol concentrations were lower 
than we had anticipated based on the patient records; half of the baseline values were below 6 
mmol/L. Two participants had blood glucose levels lower than 6.5 mmol/1 at baseline. 
All participants completed the study successfully. Complaints of flatulence were 
significantly higher (P=0.008) during the supplementation with fructo-oligosaccharides than during 
the placebo treatment. No other gastro-intestinal complaints were reported. 
Compliance, expressed as the proportion of supplements not returned, was 100% during 
both treatments. The diaries did not reveal relevant differences between the treatments in physical 
activity patterns, medication used and eating, drinking or lifestyle behavior. Body weight decreased 
significantly over time and was 0.6 kg lower at the end of the study compared to baseline (p=0.008). 
However, there were no differences in weight difference between the treatments. Mean body weight 
was 81.7 (SD 14.0) kg on placebo and 81.9 (SD 14.4) kg on fructo-oligosaccharides. 
There were no differences in the average daily intakes of energy, protein, fat, carbohydrates 
or dietary fiber (table 2). 
Blood parameters 
Fasting concentrations of blood glucose, serum acetate, serum total cholesterol, HDL and LDL 
cholesterol and triacylglycerol did not differ between treatments. Table 3 gives the average values 
during both treatments. Figure 1 shows the mean differences with their 95% confidence intervals. 
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Table 2. 
Reported dietary intake of 20 diabetic patients after supplementation with glucose (placebo) or 
fructo-oligosaccharides1 
Treatment 
Glucose (placebo) Fructo-oligosaccharides 
Energy intake (MJ) 6.6 ± 3.2 6.1 ± 2.1 
Carbohydrate intake (% EI) 38.5 ± 7.5 39.4 ± 7.2 
Fat intake (% EI) 39.9 ± 9.0 36.7 ± 9.6 
Protein intake (% EI) 21.5 ± 6.2 23.2 ± 6.1 
Dietary fibre (g/MJ) 2.1 ± 0.9 2.1 ± 0.8 
1
 Values are expressed as mean ± SD, supplements are not included. 
Table 3. 
Fasting serum lipids, serum acetate and blood glucose in 20 diabetic patients after 20 days of daily 
supplementation with glucose (placebo) or fructo-oligosaccharides' 
Treatment 
Glucose (placebo) Fructo-oligosaccharides 
mmol/L 
Total cholesterol 
HDL cholesterol 
LDL cholesterol 
Triacylglycerol 
Free fatty acids 
Acetate 
Glucose 
6.01 
1.09 
3.80 
2.44 
0.83 
0.11 
8.59 
± 
± 
± 
± 
± 
± 
± 
1.18 
0.25 
1.04 
0.79 
0.28 
0.02 
2.66 
6.21 
1.12 
3.99 
2.56 
0.75 
0.11 
8.61 
± 
± 
± 
± 
± 
± 
± 
1.29 
0.23 
0.91 
1.22 
0.26 
0.02 
2.61 
1
 Values are expressed as mean ± SD. 
Eight patients showed higher total cholesterol values on the placebo treatment than on the fructo-
oligosaccharide treatment, one showed no difference, and 11 had lower values on placebo. For 11 
patients, the concentration of blood glucose was higher on placebo than on the fructo-
oligosaccharides, one patient showed no difference, and eight patients had lower values on placebo. 
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Data analyses for men and women separately did not reveal differences of the treatments 
between the sexes (data not shown). The sample size was too small to perform analyses in 
smaller subgroups such as patients using similar medication. 
mmol/L 
•& -& J?~ •& J? ^ 
£ $ # # J 
6* 
Figure 1. Net effect (mean and 95% confidence interval) of fructo-oligosaccharides on fasting 
concentrations of serum lipids, serum acetate and blood glucose in 20 diabetic patients, computed as 
the effect of a 20 days period of supplementation with fructo-oligosaccharides minus the effect of a 
placebo (glucose). 
Discussion 
Our findings show that consumption of 15 grams of fructo-oligosaccharides does not significantly 
affect blood glucose and serum lipids in non-insulin dependent diabetic patients. 
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Compliance of the participants, statistical power of the experiment and dietary intakes during 
the study 
We believe that the lack of effect in our study can not be explained by insufficient compliance of 
the participants, a low statistical power, changes in intake of other nutrients, or by the fact that we 
studied both men and women. 
Both reported compliance and compliance judged by the supplements that were not returned 
was near 100% and did not differ between treatments. Furthermore, consumption of the fructo-
oligosaccharide supplements was confirmed by the anticipated increase in flatulence during this 
treatment. 
Based on studies with soluble dietary fibers, such as pectin and guar gum, we hypothesized 
that 15 grams of fructo-oligosaccharides would decrease serum cholesterol by 10%. In our study, 
we were able to detect a decrease of 6.1%> with 80% confidence and of 1.2% with 90% confidence. 
We were able to detect changes smaller then 10% in 3 out of 6 of the other parameters. As the 
variation in response was high for the variables acetate, free fatty acids and triacylglycerol, the 
detectable effects were also higher (15-21%), with 90% confidence). We conclude that the study 
design was powerful enough to detect biologically relevant changes in our main outcome variables. 
Contrary to our expectations, we observed small, non-significant increases in all of our variables, 
except for free fatty acids. The 9.2%> decrease in free fatty acids might have been a true change, but 
was not detectable with the used study design. 
We checked the dietary intakes of the patients by means of 2-days food records in both 
treatment periods. Reported energy intakes were very low in both men (8 MJ/d) and women (5 
MJ/d) as compared to mean intake of Dutch men (10.5 MJ/d) and women (7.9 MJ/d) (Anonymous, 
19936), probably because of underreporting. The results however revealed no differences in the 
average intakes of energy, macronutrients or dietary fiber between treatments. There were also no 
differences between treatments in body weight. It is thus unlikely that the participants adjusted their 
dietary habits in response to the treatment. 
Both men and women were included in our study population. It is often believed that women 
are less suitable patients for studying dietary effects on colonic fermentation or serum lipids because 
of confounding effects of the menstrual cycle (Kim & Kalkhoff, 1979; McBurney, 1991) or of the 
use of oral contraceptives (Demacker et al, 1982). However, all women were postmenopausal and 
none used oral contraceptives. 
Dose and duration of the treatment 
The study tested the effects of daily supplementation with 15 grams of fructo-oligosaccharides for 
20 days. This choice of dose and duration of the treatment might have influenced the results. 
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To our experience, a dose of 15 grams gives rise to some gastrointestinal complaints, in particular 
flatulence, but is still acceptable to healthy humans (Alles et al, 1996). By supplementing the diet 
with 15 grams of fructo-oligosaccharides, we at least doubled the average daily intake of inulin plus 
fructo-oligosaccharides, which is estimated to be 1-10 g/d dependent on population and method of 
food analysis (Van Loo et al, 1995). It is thus unlikely that effects of the supplemented fructo-
oligosaccharides were masked by effects of naturally occurring fructo-oligosaccharides. 
Our results do not agree with those of several studies in rats (Levrat et al, 1994; Fiordaliso et 
al, 1995; Kok et al, 1996; Delzenne et al, 1993). However, this discrepancy can be explained by 
species differences or incomparable doses. In all rat-studies, animals were fed a 10% fructo-
oligosaccharides diet, with a mean food intake of 23 g/d and an average body weight at the end of 
study of 300 g. For rats, the intake of fructo-oligosaccharides per kilogram of metabolic weight 
(body weight °75) was thus 5.7 g/kg. For our diabetic patients, with a mean body weight of 81 kg, 
the average intake was 0.6 g/kg metabolic weight. Rats thus consumed a dose of fructo-
oligosaccharides which is comparable with a human consumption of 150 g per day, which is clearly 
not in the feasible range of intakes in humans. 
In the human study of Yamashita et al (1984) 8 g of fructo-oligosaccharides per day lowered 
fasting glycaemia and serum lipids. The control group in their study consumed 5 g/d of sucrose 
which has a somewhat higher energy content than 8 g of fructo-oligosaccharides, but this difference 
is too small to explain their results. Participants in the study of Yamashita were patients with 
uncontrolled diabetes, who had a mean blood glucose level of 11 mmol/L at baseline. Their mean 
cholesterol level was 6.3 mmol/L at baseline. The largest treatment effects were found in the most 
hypercholesterolemic patients. The participants in our study were under strict medical control for 
their diabetes. Mean baseline concentration of blood glucose was 8.4 mmol/L and that of total 
serum cholesterol was 5.95 mmol/L. We used patients' blood values of their most recent medical 
check-up as a criterion for inclusion in the study. Baseline values in the experiment however were 
mostly lower, possibly due to differences in the analytical methods between the Human Nutrition 
laboratory and the Nijmegen Hospital Laboratory or due to the fact that our patients fasted 
overnight before blood was taken. The apparent effectiveness of medication in our patients might 
have masked a possible effect of the fructo-oligosaccharides. 
It is possible that 20 days of supplementation might have been too short to induce 
differences in glucose and lipid metabolism. However, we think this is unlikely as serum lipid 
concentrations stabilize within 2 weeks after a dietary change (Stasse-Wolthuis et al, 1980; Keys et 
al, 1965; Wolever et al, 1994) in healthy humans and hypercholesterolemic patients. Dietary effects 
on fasting glycaemia in non-insulin dependent diabetic patients can be established within 2 weeks 
(Crapoefa/, 1986). 
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Effects of short-chain fatty acids on glucose and lipid metabolism 
The potential impact of fructo-oligosaccharides on glucose and lipid levels is based on the 
hypothetical effects of short-chain fatty acids from fermentation on glucose and lipid metabolism. 
Several researchers found increased serum levels of acetate after treatment with other types 
of non-digestible carbohydrates (Muir et al, 1995; Pomare et al, 1985; Jenkins et al, 1991; 
Rumessen et al, \992b). We did not observe this but we might have missed the effect because we 
measured fasting and not post-prandial serum concentrations of acetate. Fructo-oligosaccharides are 
rapidly fermented and a peak concentration of serum acetate would be expected after a few hours, as 
is seen with lactulose (Rumessen et al, 19926; Pomare et al, 1985). 
Acetate and propionate have dissimilar effects on glucose and lipid metabolism. Acetate is 
thought to facilitate the cellular uptake of glucose by suppressing lipolysis and thereby lowering the 
amount of free fatty acids in serum. Free fatty acids compete with glucose to enter the cell (Akanji 
et al, 1989; Akanji & Hockaday, 1990; Thorburn et al, 1993). The in vivo effect of propionate on 
fasting glycemia seems to depend on the route of administration. Rectal infusion of propionate 
stimulates gluconeogenesis (Wolever et al, 1991; Carman et al, 1993; Boillot et al, 1995), whereas 
orally administered propionate tends to reduce glycemia (Wolever et al, 1995; Wolever et al, 1991). 
Acetate may act as a precursor for cholesterol synthesis (Wolever et al, 1995; Wolever et al, 1991), 
whereas propionate might decrease the use of acetate as a precursor of cholesterol syntheses 
(Wolever et al, 1991; Wolever et al, 1995; Wolever et al, 1996; Kok et al, 1996). Thus, acetate is 
thought to decrease glycaemia and increase cholesterol levels, whereas fermentation-derived 
propionate probably increases glucose production and decreases cholesterol levels. 
The in vitro fermentation of both lactulose and fructo-oligosaccharides was tested by Luo et 
al (Luo et al, 1996). The authors conclude that the ratio of acetate:propionate is higher after 
lactulose fermentation (11.4) than after fructo-oligosaccharide fermentation (5.4), which was 
confirmed by Wang and Gibson (1993). In vivo, acetate seems to dominate the net effects in the 
case of lactulose. Jenkins et al (1991) showed increased levels of total cholesterol after lactulose 
supplementation. With fructo-oligosaccharides the net effect on glucose and lipid levels seems to be 
zero. 
Conclusions 
We conclude that fructo-oligosaccharides do not have important effects on blood glucose and serum 
lipids in non-insulin dependent diabetic patients who are under strict medical control. The lack of 
effect in our study could not be explained by changes in dietary intake, insufficient power or non-
compliance of the patients. Thus, our findings do not suggest that fructo-oligosaccharides are an 
effective means to favorably affect serum lipids or glucose. However, it remains possible that other 
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type non-digestible oligosaccharides, with different fermentation patterns do have effects on serum 
lipids or glycaemia. 
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Introduction 
This thesis embodies four human trials in which we studied the physiological effects of dietary 
fructo-oligosaccharides and transgalacto-oligosaccharides. The studies were aimed at investigating 
fermentation of the oligosaccharides, effects on the composition of the intestinal microflora, on 
colon cancer risk markers and on glucose- and lipid metabolism. First, the main findings are 
summarized and related to other studies. Then, the methodology used in the studies is discussed. 
Finally, recommendations for further research are given at the end of this chapter. 
Main findings in relation to other studies 
Fermentation 
Because of the non-digestibility of the oligosaccharides, most of the molecules will survive passage 
through the upper part of the gastrointestinal tract and reach the colon unchanged, were they may 
serve as a substrate for the colonic microflora. Oligosaccharides will be degraded by microbial 
glycosidases into monomeric or dimeric material, which can be transported into the bacterial cells 
and metabolized into energy and end products such as short-chain fatty acids and hydrogen. 
Fecal excretion of oligosaccharides 
Apparent fermentability can be determined by analyzing the fecal excretion of the specific 
oligosaccharides added to the diet. We used high performance anion exchange chromatography to 
quantify the amount of oligosaccharides in feces. In Chapter 2, we showed that feces of healthy 
volunteers adapted to a diet with 5 or 15 g of extra fructo-oligosaccharides per day, contained no 
oligomers derived from the supplement. These results were confirmed by Molis et al (1996). In 
Chapter 3, the fate of fructo-oligosaccharides was determined in patients with an ileal pouch-anal 
anastomosis. In these patients the colon is removed and part of the distal ileum is used to construct 
an ileal reservoir. Although the fermentation capacity of the ileal pouch was considered to be much 
smaller than that of the colon, bacterial fermentation obviously took place to an appreciable extent, 
as only 17% of fructo-oligosaccharides were recovered from feces. 
In Chapter 4, the fecal excretion of transgalacto-oligosaccharides was measured in healthy 
volunteers using different doses of transgalacto-oligosaccharides in the diet (0, 7.5 and 15 g/d). No 
transgalacto-oligomers were recovered in feces of any of the subjects. 
98 
General discussion 
Gas production 
The gases hydrogen and methane that are produced by colonic fermentation are partly absorbed into 
the blood and can be measured in breath. In Chapter 2 and 3, we studied the hydrogen response to 
fructo-oligosaccharides and observed significant increases of the integrated breath hydrogen 
excretion over 24 hours, at a dose of 15 g/d. Several other studies showed similar gaseous responses 
to consumption of fructo-oligosaccharides (Gibson et al, 1995a; Stone-Dorshow & Levitt, 1987; 
Rumessen et al, 1990). Stone-Dorshow and Levit (1987) showed a breath hydrogen response after 
consumption of fructo-oligosaccharides that was comparable to that after lactulose. Prolonged 
intake (12 d) of fructo-oligosaccharides resulted in higher breath hydrogen excretion. Rumessen et 
al (1990) also showed that the hydrogen production increased with increasing doses of fructans. On 
the other hand, in a study by Gibson et al (1995a), breath methane was not affected by fructo-
oligosaccharides. 
In Chapter 4, a significant increase in the concentration of breath hydrogen was found after 
consumption of 15 g of transgalacto-oligosaccharides per day, but not after consumption of 7.5 g 
per day. Tanaka et al (1983) also reported on the excretion of hydrogen after supplementation with 
transgalacto-oligosaccharides. They observed an increase in hydrogen after administration of 0.5 
g/kg body weight. This was confirmed by a study of Bouhnik et al (1997) who observed a high 
excretion of hydrogen after supplementation with 10 g/d. In their study, prolonged ingestion of 
transgalacto-oligosacccharides led to a significant drop in the expired hydrogen. Transgalacto-
oligosaccharides did not significantly affect the excretion of methane in this study. 
At doses of fructo- and transgalacto-oligosaccharides below 10 g/d, the effects on the 
excretion of hydrogen are less profound and probably masked by effects of other dietary 
components. 
Fermentation related events, such as excessive gas production in the colon, may cause some 
gastro-intestinal discomfort. In Chapter 2, we quantified gastro-intestinal discomfort by using a 
scoring system in which subjects scored the severity of symptoms on a four point scale. We 
observed an increased flatulence with increasing amounts of fructo-oligosaccharides (0, 5 and 15 
g/d). All other scores were low and equal for the three treatments. Similar results were found in a 
study by Stone-Dorshow and Levit (1987). Briet et al (1995) evaluated the tolerance to a sweetener 
containing fructo-oligosaccharides. Hereto, fructo-oligosaccharides were ingested throughout the 
day either occasionally (one a week) or regularly (every day). Daily doses were increased until 
diarrhea and/or a symptom (such as cramps, bloating, flatus) rated as "severe" occurred. Excessive 
flatus was observed at doses higher than 30 g/d. Borborygmus and bloating appeared at higher 
levels (>40 g/d) and cramps at doses >50 g/d. The authors also concluded that chronic consumption 
of fructo-oligosaccharides does not improve tolerance. 
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We did not quantify the gastro-intestinal complaints after consumption of transgalacto-
oligosaccharides. Ito et al (1990) studied the effect of transgalacto-oligosaccharides on feelings of 
abdominal discomfort in humans given different doses (0, 2.5, 5 and 10 g/d; for 7 d). Although the 
frequency of fullness, flatulence and abdominal pain increased with increasing doses of 
transgalacto-oligosaccharides, the increase was only significant for fullness. 
Fecal short-chain fatty acids andpH 
Several rat studies show an increase of cecal short-chain fatty acids pools and a decrease in cecal pH 
after supplementation with either fructo-oligosaccharides (Djouzi & Andrieux, 1997; Campbell et 
al, 19976; Younes et al, 1995; Levrat et al, 1991) or transgalacto-oligosaccharides (Rowland & 
Tanaka, 1993; Djouzi & Andrieux, 1997; Levrat et al, 1991). Human studies so far did not detect 
any effect of non-digestible oligosaccharides (Munster et al, 1994ft; Gibson et al, 1995a; Bouhnik 
et al, 19966) on fecal pH or concentrations of short-chain fatty acids. In Chapter 2, 3 and 4 we also 
failed to show an increase in the concentration of short-chain fatty acids or a decrease in pH in 
response to consumption of fructo-oligosaccharides or transgalacto-oligosaccharides. 
Bacterial glycosidase activity 
Gut bacteria degrade non-digestible carbohydrates by using a wide range of depolymerizing 
enzymes. Dietary components may affect the metabolic activity of the microflora by inducing these 
enzymes. Bouhnik et al (19966) showed an increase in B-fructosidase activity after consumption of 
fructo-oligosaccharides. We showed an enhanced activity of 13-galactosidase by specific substrate 
induction by transgalacto-oligosaccharides. This was also found by Djouzi et al (1997) in rats. Also 
non-specific enzymes may be altered in response to consumption of non-digestible 
oligosaccharides. We observed a decreasing effect of fructo-oligosaccharides on the activity of a-L-
arabinofuranosidase, which is the enzyme that degrades arabinosyl linkages from various 
hemicelluloses (Kaji, 1984). These non-specific effects may be due to either changes in microflora 
composition or shifts in the metabolic activity of individual species of bacteria. 
Healthy volunteers thus ferment fructo-oligosaccharides and transgalacto-oligosaccharides 
completely. Consumption of non-digestible oligosaccharides leads to a clear gaseous response, 
reflected in an elevated excretion of breath hydrogen and often to more complaints of flatulence. 
Short-chain fatty acids are produced simultaneously with hydrogen by most bacteria (Cummings & 
MacFarlane, 1991). MacFarlane et al (MacFarlane et al, 1992), in an autopsy study of victims of 
sudden death, found high amounts of short-chain fatty acids in the proximal colon and lower 
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amounts towards the end of the gastrointestinal tract. They attributed this to rapid absorption of the 
acids by the colonic mucosa. In Chapter 3, a similar rapid absorption by the pouch mucosa could 
explain why we did not find significant effects on the fecal excretion of short-chain fatty acids or 
pH in this study. The fraction of the short-chain fatty acids found in feces does obviously not 
correspond to their intra-colonic production. An alternative biomarker for the colonic metabolic 
activity might be the glycolytic activity of intestinal bacteria in feces. In Chapter 5 we showed that 
substrate specific changes of bacterial glycosidase activity can be measured in feces. 
The intestinal microflora 
Oligosaccharides from human breast milk are known to have a so-called bifidogenic effect and are 
responsible for the predominance of bifidobacteria in the feces of breast-fed infants. The responsible 
compounds are B-galacto-oligosaccharides with various complex structures, consisting of glucose, 
galactose, N-acetylglucosamine, fucose and sialic acid (Coppa et al, 1993; Carlson, 1985; Gronberg 
et al, 1989). Growth of bifidobacteria in adults might possibly be manipulated by adding other types 
of oligosaccharides to the diet. Several human studies investigated the effects of fructo-
oligosaccharides (Gibson et al, 1995a; Bouhnik et al, 1996a; Bouhnik et al, 19966; Buddington et 
al, 1996) or transgalacto-oligosaccharides (Ito et al, 1990; Tanaka et al, 1983; Bouhnik et al, 1997; 
Ito et al, 1993a; Hayakawa et al, 1990) on the composition of the intestinal microflora. They all 
found a significant increase in the fecal bifidobacterial counts. In Chapter 4, we found no effects of 
transgalacto-oligosaccharides on the composition of the fecal microflora of healthy volunteers, 
when tested in a controlled feeding trial against a placebo treatment. 
Our volunteers were healthy and not especially selected for having a small number of 
bifidobacteria. In healthy volunteers with a stable and healthy balance in their microfloral 
population, it might be difficult to get diet-induced changes. Also, our findings do not exclude the 
possibility that changes in the composition of the flora occurred in the proximal part of the colon. 
Colon cancer risk markers 
As indicated in figure 3 of Chapter 1, there are several mechanisms by which carbohydrate 
fermentation might affect colon cancer risk. In this thesis we measured the following colon cancer 
risk markers: stool weight, fecal concentrations of butyrate, bile acid profiles, fecal concentrations 
of protein degradation products and the activity of several glycolytic enzymes. 
Stool weight 
We hypothesized that non-digestible oligosaccharides would increase bacterial proliferation and 
thereby bacterial mass. As fecal bacteria contribute considerably to fecal weight (Stephen & 
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Cummings, 1980; Hill, 1995), we expected to find an increase in total fecal weight, with a shift to a 
more watery constitution as bacteria are 80% water (Stephen & Cummings, 1980). Due to the 
laxative effects of the larger fecal mass, we expected to find a higher frequency of defecation. 
In healthy volunteers, we did not observe any significant changes in total stool weight or 
frequency of defecation in response to consumption of either fructo-oligosaccharides (Chapter 2) or 
transgalacto-oligosaccharides (Chapter 4). We did find a 6.3% higher nitrogen density of the fecal 
dry matter on transgalacto-oligosaccharides, which points to an increase in the bacterial mass 
(Stephen & Cummings, 1980; Levrat et al, 1993; Younes et al, 1995). The effect of this increase on 
total stool weight, which is theoretically 9.5 g per day, was probably too small to detect. Gibson et 
al (1995a) showed higher stool weights and an enhanced nitrogen excretion on fructo-
oligosaccharides. In pouch patients (Chapter 3), fructo-oligosaccharides significantly increased 24 h 
fecal weight by 20.3%. The unfermented oligosaccharides and probably also the extra biomass were 
responsible for the increase in fecal weight. 
Fecal butyrate 
We did not show any increases in the fecal concentration of butyrate after consumption of either 
fructo-oligosaccharides or transgalacto-oligosaccharides (see under "fermentation"). 
Fecal bile acids 
We were unable to show any effects of transgalacto-oligosaccharides on the concentration of bile 
acids in fecal water (Chapter 4). We hypothesized that acidification of the colon content, as a result 
of the fermentation of oligosaccharides, would lead to precipitation of the soluble deconjugated bile 
acids (Fini & Roda, 1987; Bruce, 1987; Munster & Nagengast, 1993) and to a suppression of the 
bacterial conversion of primary to secondary bile acids (Christl et al, 1997; Munster & Nagengast, 
1993). We therefore expected to find a lower concentration of bile acids in fecal water and a smaller 
ratio of hydrophobic to hydrophilic bile acids. Although we have no information on the acidification 
in the colon, we did not find a decrease in the fecal pH. Due to the high within-subject variation, 
only large effects (of 50-60%) on the concentration of bile acids were detectable in our study. 
Although such effects have been shown by others, using different dietary treatments (Munster et al, 
1994ft; van Faassen et al, 1996; Nagengast et al, 19886), we might have missed possible smaller 
effects. 
Protein fermentation products 
In Chapter 3 we found indications that fructo-oligosaccharides would decrease protein 
fermentation. In patients with an ileal pouch anal anastomosis, we found a significant lower fecal 
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excretion of isobutyrate and isovalerate, which are short-chain fatty acids that originate from the 
bacterial breakdown of amino acids (Geypens et al, 1997; MacFarlane & MacFarlane, 1993; 
Rasmussen et al, 1988; Zarling & Ruchim, 1987). Similar effects were observed in other studies, 
using galacto-oligosaccharides (Ito et al, 1993a) or lactulose (Mortensen et al, 1990). Protein 
fermentation produces not only amino acid-derived short-chain fatty acids, but also indoles and 
ammonia. These products might have a toxic effect on the mucosa (Birkett et al, 1996; Clausen & 
Mortensen, 1992a; Clinton et al, 1988; Bone et al, 1976). We hypothesized that transgalacto-
oligosaccharides would decrease protein fermentation products by two mechanisms. Firstly, we 
expected to find a depression of protein fermentation, as seen in pouch patients after consumption of 
fructo-oligosaccharides. Also, when transgalacto-oligosaccharides are used as an energy substrate 
by the bacteria, nitrogen sources such as amino acids and ammonia are used for the subsequent 
increase in bacterial growth (Birkett et al, 1996; Mortensen et al, 1990; Levrat et al, 1993). In 
healthy volunteers, we did not show any decreasing effect of transgalacto-oligosaccharides on the 
fecal concentration of protein degradation products ammonia, indoles and skatoles, an effect shown 
earlier by Ito et al (1993a) and Djouzi et al (1997). We also did not observe a decrease in the 
concentration of the short-chain fatty acids that originate from bacterial breakdown of amino acids. 
Bacterial glycosidase activity 
By affecting the composition and activity of the intestinal microflora, the activity of bacterial 
enzymes might be altered. Several studies showed that dietary fiber may lower some of the fecal 
bacterial enzymes that have adverse effects in the colon (Reddy et al, 1992; Mallett & Rowland, 
1987), such as 13-glucuronidase and C-glucosidase. We (Chapter 5) and others (Djouzi & Andrieux, 
1997; Bouhnik et al, 1996a; Kleessen et al, 1997; Bouhnik et al, 19966) did not show any effects of 
fructo-oligosaccharides or transgalacto-oligosaccharides on the activity of these enzymes. 
Although there are many hypotheses linking fermentation of non-digestible oligosaccharides to 
lower putative risk factors for colon cancer, our results do not give sufficient evidence to support 
any of them. It should be noted that there is no conclusive evidence that the biomarkers that were 
used are indeed causally related to the development of colon cancer. We did not measure the 
cytotoxicity of fecal water or the colonic mucosal proliferation in rectal biopsies after consumption 
of the oligosaccharides. 
Glucose- and lipid metabolism 
Short-chain fatty acids that are produced during fermentation can be absorbed by the colonic 
mucosa (Rombeau & Kripke, 1990; Pomare et al, 1985; Cummings et al, 1987a) and used as fuel 
for the mucosa (butyrate) or entered into the portal blood (acetate and propionate). Acetate and 
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propionate may both affect systemic glucose (Akanji et al, 1989; Akanji & Hockaday, 1990; 
Thorburn et al, 1993; Wolever et al, 1991; Carman et al, 1993; Boillot et al, 1995) and lipid 
metabolism (Wolever et al, 1995; Wolever et al, 1991; Wolever et al, 1996; Kok et al, 1996). Via 
these fermentation products, non-digestible oligosaccharides may affect glucose and lipid 
metabolism. In Chapter 6, we showed that fructo-oligosaccharides do not favorably affect fasting 
glycaemia or serum lipids in non-insulin dependent diabetic patients. Other studies with healthy 
volunteers also failed to show any effect on fasting blood glucose or lipids (Luo et al, 1996; 
Pedersen et al, 1997). These results do not agree with those of several studies in rats (Kok et al, 
1996; Fiordaliso et al, 1995; Levrat et al, 1994; Delzenne et al, 1993). However, this discrepancy 
can partly be explained by incomparable doses of fructo-oligosaccharides. In all rat-studies, animals 
were fed diets containing approximately 5.7 g fructo-oligosaccharides per kg of metabolic weight. 
For our patients, the average intake was 0.6 g per kg of metabolic weight. In a human study by 
Yamashita et al (Yamashita et al, 1984), fructo-oligosaccharides significantly reduced fasting 
glycaemia and serum lipids in patients with uncontrolled diabetes. The participants in our study 
were under strict medical control for their diabetes. 
Methodological considerations 
Storing and freezing feces before microbiological analyses 
Collection of stools in dietary intervention trials is often difficult to control due to variations in 
defecation patterns. Often, volunteers are asked to freeze their stools at home or at the laboratory, 
immediately after defecation. The method of collection is of importance in the quality of the 
subsequent fecal analyses. Methods for quantifying bacteria in feces are based on viable counts on 
selective media. Because of the high vulnerability of most bacteria, special conditions must be 
created to ensure survival during sampling, processing and analysis. The effect of preservation of 
the stool sample on the bacterial counts in feces was studied by Crowther et al (1971). They 
compared different methods of storing at different freezing temperatures. After freezing at -80 ° C, 
all species tested were recovered from suspensions of feces frozen in broth, with glycerol as a 
protective agent. No significant changes were observed. In a more recent study (Bollongue, 1997), 
Ballongue tested the survival of bifidobacteria during storage and confirmed the results of 
Crowther. Both studies based their conclusions on the analysis of one single fecal sample. It is 
possible that the sample size was too small and that errors in the measurement masked a possible 
effect of storing and freezing. We replicated the validation of Crowther with a larger sample size of 
different stools (n=23). The methods for the bacterial enumeration are similar as those described in 
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Chapter 4. The results (Figure 1), indicate a significant reduction in total aerobes, E.coli and 
bacteroides and an increase in Clostridia, caused by storing the feces in the described way. 
Log CFU / g of feces 
Figure 5. Effect of storing and freezing fecal samples (n=23), according to the method of Crowther 
et al (1971), on the composition of the intestinal microflora. Values are logarithms of the mean 
counts of colony forming units (CFU) per gram of feces in fresh samples (black bars) or after 
freezing (white bars). * Mean values are significantly different from those in the fresh samples 
(PO.05). 
We conclude that freezing the feces before using selective media in determining fecal bacteria, 
significantly affects the bacterial counts, with different effects for different bacterial groups. 
Design of studies on diet and colonic microflora 
To determine the required sample size for the study described in Chapter 4, we measured the intra-
individual variation in bacterial counts over a period of 2 weeks. The within-subject variation was 
only 5% for bifidobacteria and below 11% for all other bacteria that were tested (Table 1). 
Table 1. 
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Total aerobes 
E. coli 
Total anaerobes 
Bifidobacteria 
Bacteroides fragilis-group 
Lactobacilli 
6.4 
6.4 
9.7 
8.6 
8.6 
6.8 
Chapter 7 
Intra-individual variation in fecal bacterial counts as measured in 3 different stools over a period of 
2 weeks1. 
Bacteria Mean CV% 
8~3 
8.4 
3.6 
4.9 
6.4 
10.9 
1
 Values are logarithms of the mean counts of colony forming units per gram of feces. CV%, day-to-day 
variation in bacterial counts. 
In the study described in Chapter 4, bifidobacterial counts increased by 4% independently of the 
treatment, but the differences between the increases on placebo and transgalacto-oligosaccharides 
were not statistically significant. With the exception of our study and 2 others (Ito et al, 1990; 
Bouhnik et al, 19963), all studies on the effects of non-digestible oligosaccharides on the 
composition of the intestinal microflora were done using a linear study design, with measurements 
before and after the treatment. Without the placebo group, the conclusion from our study would 
have been that transgalacto-oligosaccharides selectively increase bifidobacteria in the gut. 
We conclude that it is necessary to compare the effects of non-digestible oligosaccharides 
with a control treatment, to exclude possible time effects. 
Background diet 
The background diet of our volunteers was not controlled in Chapters 2, 3, 5 and 6. Although we 
did not find any significant deviations in eating and drinking behavior in the dietary records, it 
remains possible that dietary components masked the effects of our intervention. The volunteers in 
Chapter 2 e.g. consumed an habitual diet with 2.9 gram of dietary fiber per MJ. In Chapter 4, we 
used a controlled feeding trial to test the effects of transgalacto-oligosaccharides. We chose for a 
background diet with a relative low fiber content (1.5 g/MJ) to overcome the above mentioned 
masking problems. The chosen diet was also high in protein (16%) in order to increase fermentation 
of dietary proteins (Gibson et al, 1976; Geypens et al, 1997). We hereby hoped to increase the 
chance of showing inhibiting effects of the oligosaccharides on this protein fermentation. Levrat et 
al (1993) studied the effects of the fermentable carbohydrate inulin in rats fed a high versus a 
moderate protein diet. They showed that use of ammonia as a source of bacterial growth was 
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increased on inulin, but more evident when the dietary protein level was moderate. In high protein 
diets, uremia and flux of urea from plasma to colon is high and an important determinant of fecal 
concentrations of ammonia (Levrat et al, 1993; Younes et al, 1995). This mechanism might explain 
the negative results in our study with regard to protein fermentation products. 
Although the day-to-day variation in the composition of the intestinal microflora seems to be 
small, it is known from animal studies that sudden extreme changes in diet can have profound 
effects on this composition (Koopman, 1984). The low-fiber, high-protein diet that we provided in 
our study with transgalacto-oligosaccharides might have been too extreme for some of our 
volunteers. We hypothesize that at first, the diet upset the balance of microflora of the volunteers 
and that the flora then gradually adapted to the changes in substrate supply. This is our only 
possible explanation for the increase in bifidobacteria that was found independently of the 
treatment. 
We conclude that the background diet is of great importance in studies on the effects of diet 
on the composition and activity of the intestinal microflora. 
Recommendations 
1. More information on the exact content of non-digestible oligosaccharides in foods is necessary, 
to be able to assess the possible effects of these compounds on human health in epidemiological 
studies. 
2. There is a need for high quality and practical methods for measuring the composition of the 
intestinal microflora. The recent development of molecular techniques for this purpose is 
promising. 
3. Effects of fructo-oligosaccharides and transgalacto-oligosaccharides on the composition of the 
intestinal microflora need to be confirmed in placebo controlled intervention trials. 
4. Studies on non-digestible oligosaccharides should not only focus on expected positive effects. 
There is little information on the role of non-digestible oligosaccharides in the potentially 
harmful effects of: extreme pH decreases in the proximal colon, increases of proteolysis in the 
distal colon, in vivo growth and survival of specific pathogens or bacterial overgrowth in the 
small intestine. 
5. Fructo-oligosaccharides and transgalacto-oligosaccharides are probably fermented in the 
proximal colon. In order to provide the whole colon with fermentable substrate, it might be 
useful to test combination effects of non-digestible oligosaccharides with a more slowly 
fermentable carbohydrate. 
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In conclusion 
Fructo-oligosaccharides and transgalacto-oligosaccharides are completely fermented in the colon of 
healthy individuals, which leads to a clear gaseous response. We did not find any evidence that they 
beneficially affect putative colon cancer risk markers, the composition of the intestinal microflora or 
glucose and lipid metabolism. It remains possible that they have effects in other study-populations, 
when tested against another background diet or when combined with other fermentable substrates. 
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Oligosacchariden komen van nature voor in veel gewassen die worden gebruikt als grondstof bij de 
productie van voedingsmiddelen. De oligosacchariden die voorkomen in planten zijn vaak niet 
verteerbaar in het bovenste gedeelte van het menselijke spijsverteringskanaal en worden meestal 
beschouwd als voedingsvezel. Met de officiele AOAC analyse voor totaal voedingsvezel zijn ze 
echter niet in voedingsmiddelen te meten. 
De studies in dit proefschrift beschrijven de fysiologische effecten van twee typen niet-
verteerbare oligosacchariden: fructo-oligosacchariden (Raftilose P95®, ORAFTI, Tienen, Belgie) en 
transgalacto-oligosacchariden (Elix'or®, Borculo Whey Products, Borculo, Nederland). De 
oligosacchariden in Raftilose® worden gemaakt van inuline dat wordt geextraheerd uit de wortel van 
cichorei. De oligomeren zijn opgebouwd uit fructose-eenheden met of zonder glucose molecuul. 
Elix'or® wordt gemaakt door middel van enzymatische transgalactosylering van lactose. Het bestaat 
uit verschillende oligomeren die zijn opgebouwd uit galactose-eenheden met of zonder glucose. 
In vier placebo gecontroleerde interventie studies werd gekeken naar het lot van de 
oligosacchariden in het maagdarm kanaal en naar eindproducten van de fermentatie, en naar het 
effect van de oligosacchariden op de samenstelling van de darmflora, mogelijke risicofactoren voor 
dikke darm kanker en het glucose en lipiden metabolisme bij diabetes patienten. 
In het eerste experiment (Hoofdstuk 2) vergeleken we het effect van twee doses fructo-
oligosacchariden (5 en 15 g/d) met een placebo behandeling (glucose) op fermentatie in de dikke 
darm van gezonde mannen. Er werden geen fructo-oligosacchariden gevonden in de urine en 
ontlasting. De hoogste dosis fructo-oligosacchariden zorgde voor een significante toename van de 
24-uurs excretie van waterstof in de uitademingslucht (P < 0.05). De excretie van waterstof was ook 
hoger na consumptie van 5 g fructo-oligosacchariden, maar deze toename was niet significant. Er 
waren geen effecten op de fecale pH of op de absolute of relatieve hoeveelheid van korte keten 
vetzuren in de ontlasting. We concluderen uit deze studie dat fructo-oligosacchariden volledig 
worden gefermenteerd in de dikke darm van gezonde vrijwilligers. 
Vervolgens onderzochten we in Hoofdstuk 3 de fermentatie van twee typen niet-verteerbare 
koolhydraten, fructo-oligosacchariden en niet-verteerbaar zetmeel, in 15 gezonde patienten met een 
ileale pouch-anale anastomose. Bij deze patienten is de dikke darm verwijderd en is een deel van het 
distale ileum gebruikt om een reservoir - ofwel pouch - te maken, welke wordt verbonden met de 
anus. De schijnbare fermentatie van fructo-oligosacchariden was 83% en van niet-verteerbaar 
zetmeel 46%. Niet-verteerbaar zetmeel verhoogde de fecale excretie van butyraat met 69%, terwijl 
fructo-oligosacchariden de excretie verlaagde van het, uit de eiwit fermentatie afkomstige, iso-
butrate (met 94%) en iso-valeraat (met 77%). Fructo-oligosacchariden verhoogden het fecaal 
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gewicht (met 110 g/d) en de excretie van waterstof in uitademingslucht (met 201 ppm.h). De studie 
suggereert dat bacteriele fermentatie van niet-verteerbare koolhydraten in de pouch in grote mate 
plaatsvindt. Fructo-oligosacchariden worden voor een groot gedeelte afgebroken in de pouch en zijn 
kennelijk een gemakkelijk fermenteerbaar substraat voor de darmflora. 
In een gecontroleerde voedingsproef, beschreven in Hoofdstuk 4, onderzochten we het effect 
van twee doses transgalacto-oligosacchariden (7.5 en 15 g/d) in vergelijking met een placebo (een 
mengsel van glucose en lactose) op de samenstelling en activiteit van bacterien in de dikke darm. Er 
werden geen transgalacto-oligosacchariden gevonden in de ontlasting. De hoogste dosis zorgde voor 
een significante stijging van de waterstofconcentratie in adem met 138% (P < 0.01) en van het 
stikstofgehalte van de ontlasting met 6.5% (P < 0.05). Transgalacto-oligosacchariden hadden geen 
significant effect op de frequentie van defecatie, het gewicht van de ontlasting, de samenstelling van 
de ontlasting, de concentratie korte keten vetzuren of galzuren in fecal water, de fecale concentratie 
van ammonia, indolen of skatolen of op de fecale pH. Het aantal bifidobacterien in de ontlasting 
nam significant toe gedurende de studie maar er waren geen verschillen tussen de stijging tijdens de 
placebo-behandeling en die tijdens interventie met transgalacto-oligosacchariden. We concluderen 
uit deze studie dat transgalacto-oligosacchariden volledig worden gefermenteerd in de dikke darm. 
We konden geen positieve effecten aantonen op de fecale concentratie van toxische producten uit de 
eiwit fermentatie, op het galzuurprofiel in fecaal water, of op de samenstelling van de darmflora. 
In Hoofdstuk 5 van dit proefschrift, combineren we gegevens uit de twee studies met 
gezonde vrijwilligers (Hoofdstuk 2 en 4) om het effect van fructo-oligosacchariden en transgalacto-
oligosacchariden te onderzoeken op de bacteriele glycosidase activiteit in fecaal water. 
Transgalacto-oligosacchariden verhoogden de activiteit van P-galactosidase met 123%. Fructo-
oligosacchariden verlaagden de activiteit van arabinofuranosidase met 35%. Beide oligosacchariden 
hadden geen effect op de activiteit van glucosidase of P-glucuronidase; deze enzymen zijn 
betrokken bij de vorming van giftige stoffen. We concluderen dat oligosacchariden een substraat 
specifiek effect hebben op de glycolytische activiteit van de bacterien in de darm. Het meten van de 
activiteit van deze enzymen is een biomarker voor de metabole activiteit van bacterien in de dikke 
darm. 
In Hoofdstuk 6 onderzochten we het effect van fructo-oligosacchariden (15 g/d) in 
vergelijking met een placebo (4 g/d) op bloed glucose, serum lipiden en serum acetaat, bij niet-
insuline afhankelijke diabetes patienten. De gemiddelde inname van energie, macronutrienten en 
voedingsvezel veranderde niet tijdens de studie. De compliance was bijna 100% gedurende beide 
interventies. Fructo-oligosacchariden hadden geen significant effect op nuchtere concentraties van 
serum totaal cholesterol (95% CI van het verschil; -0.07, 0.48 mmol/L), HDL cholesterol (95% CI 
van het verschil; -0.04; 0.04 mmol/L), LDL cholesterol (95% CI van het verschil; -0.06, 0.34 
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mmol/L), serum triacylglycerol (95% CI van het verschil; -0.21, 0.44 mmol/L), serum vrije 
vetzuren (95% CI van het verschil; -0.08, 0.04), serum acetaat (95% CI van het verschil; -0.01, 0.01 
mmol/L) of bloed glucose (95% CI van het verschil; -0.37, 0.40 mmol/L). We concluderen dat het 
gedurende 20 dagen consumeren van een voedingssupplement met fructo-oligosacchariden geen 
duidelijke effecten heeft op bloed glucose, serum lipiden of serum acetaat in niet-insuline 
afhankelijke diabetes patienten. Het ontbreken van een effect was niet te wijten aan veranderingen 
in het voedingspatroon, onvoldoende statistische power of een slechte compliance van de 
proefpersonen. 
In Hoofdstuk 7 beschrijven we een aantal methodologische aspecten van het onderzoek 
zoals beschreven in dit proefschrift. In een pilotstudie hebben we onderzocht wat het effect is van 
het bewaren en invriezen van ontlasting monsters alvorens de verschillende bacterien te 
kwantificeren. Hieruit blijkt dat het invriezen van de ontlasting significante effecten heeft op de 
bacterie tellingen en dat het effect sterk afhankelijk is van het type bacterie. In een andere 
pilotstudie vonden we dat de binnen-persoons variatie in de hoeveelheid darmbacterien zeer klein is 
(< 11%). Het is opvallend dat veel studies waarin gekeken wordt naar het effect van niet-verteerbare 
oligosacchariden op de samenstelling van de darmflora, gebruik maken van een lineaire opzet, 
zonder placebo behandeling. Zonder placebo groep zou de conclusie van Hoofdstuk 4 zijn geweest 
dat transgalacto-oligosacchariden de groei van bifidobacterien stimuleren. We concluderen dat het 
belangrijk is om de effecten van niet-verteerbare oligosacchariden te vergelijken met een placebo, 
om een mogelijk tijdseffect uit te kunnen sluiten. 
Het is duidelijk dat fructo-oligosacchariden en transgalacto-oligosacchariden volledig 
worden gefermenteerd in de dikke darm van gezonde vrijwilligers. Deze fermentatie leidt tot 
gasvorming. We vonden geen bewijs voor positieve effecten van de oligosacchariden op kenmerken 
van de ontlasting die samenhangen met het risico op dikke darmkanker. We zagen geen positieve 
effecten op de samenstelling van de darmflora of op het glucose en lipiden metabolisme. Het is 
mogelijk dat fructo-oligosacchariden of transgalacto-oligosacchariden wel een effect hebben in 
andere studie populaties of in combinatie met een ander achtergronds dieet of andere fermenteerbare 
voedingsvezels. 
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Het onderzoek dat in dit boekje wordt beschreven is de afgelopen vijf jaar uitgevoerd op de 
Vakgroep Humane Voeding en Epidemiologic Het was een leuke tijd en ik vind het fijn om als 
afsluiting iedereen te bedanken die heeft bijgedragen aan de totstandkoming van het proefschrift. 
Allereerst wil ik mijn promotor en copromotor bedanken. Professor Jo Hautvast, met u heb ik een 
bijzondere band gekregen. U heeft altijd een enorm vertrouwen in mij gehad, ook toen ik na 3 jaar 
AlO-zijn besloot om mijn promotie onderzoek verder te combineren met een baan in de industrie. Ik 
heb van u geleerd om strategische beslissingen te nemen en om op de juiste momenten een vuist te 
maken. Bedankt! 
Fokko, door jouw betrokkenheid bij het onderzoek kreeg ik interesse in de voeding van de 
zieke mens. Ik heb goede herinneringen aan onze samenwerking bij de uitvoering van de pouch-
proef. Bedankt voor de gezelligheid tijdens de gezamenlijke congres-bezoeken; je hebt trouwens 
ongemerkt mijn stijl van presenteren sterk bei'nvloed (wc-plaatjes en poepverhalen). 
Dit proefschrift was een deel van een multidisciplinair onderzoeksprogramma aan de 
Landbouwuniversiteit naar de rol van niet-verteerbare oligosacchariden in voedsel en voeder. Er 
waren vier vakgroepen betrokken bij het onderzoek: Humane Voeding en Epidemiologie, 
Veevoeding, Levensmiddelenchemie en Levensmiddelenmicrobiologie. Ik wil alle leden van het 
NDO-project graag bedanken voor hun bijdrage aan mijn proefschrift. Met name noem ik mijn 3 
mede-AIO's in het project: Jos Houdijk, Ralf Hartemink en Katrien Van Laere, bedankt voor de 
goede samenwerking binnen onze club (ook bij zaken als biggen slachten). 
Lieve Katrieneke: mijn maatje vanaf de eerste NDO-vergadering. We hebben lief en leed 
gedeeld en ik weet zeker dat het zonder jou allemaal veel minder leuk was geweest! Ik heb heel veel 
van je chemie-kennis kunnen profiteren (bedankt voor het eindeloos uitleggen van de HPAEC-
plotjes) en ik merk dat ik je inbreng in mijn huidige werk soms mis. Het is fijn en ook heel logisch 
dat jij op 18 december naast me staat! 
Bij de praktische uitvoering van de experimenten hebben een groot aantal mensen geholpen in de 
keuken, op het lab en bij de begeleiding van de deelnemers. In het kader van een afstudeervak of 
stage werkten de volgende studenten mee aan mijn proeven: Jolieta Eckhardt, Liv Elin Torheim, 
Monique van Rij, Susanne Hovens, Mariska Hospers, Chantal Hukkelhoven, Monique 
Gerichhausen, Marja Rozendaal, Nicole de Roos, Rut Luttikhuis, Wytske Nutma, Olga van Aalst, 
Mieke Beemsterboer, Jannet Grave. Bedankt voor jullie inzet en enthousiasme! 
Een groot deel van de laboratorium-analyses werd uitgevoerd op het lab van de vakgroep. 
Jan Harryvan, Robert Hovenier, Marga van der Steen, Paul Hulshof, Joke Barendse, Truus 
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Kosmeijer, Frans Schouten, Peter van de Bovenkamp, Janny Bos, Meijke Booy, Pieter Versloot: 
allemaal hartelijk bedankt voor jullie (hulp bij) analyses en voor de gezellige koffie-uurtjes. Verder 
werden een aantal analyses uitgevoerd op het lab van de afdeling gastroenterologie in Nijmegen. Ik 
wil met name Albert Tangerman bedanken voor zijn bijdrage aan het onderzoek. Voor de analyses 
van oligosacchariden in ontlasting, urine en voedingsmiddelen kon ik terecht op de vakgroep 
Levensmiddelenchemie. Ik wil Katrien Van Laere, Margret Bosveld, Henk Schols en Mark Dignum 
graag bedanken voor hun enthousiasme en voor de hoge kwaliteit van de analyses. In samenwerking 
met de vakgroep Levensmiddelenmicrobiologie konden we een geavanceerd systeem opzetten voor 
het snel en zorgvuldig analyseren van de darmflora. Ik wil Ralf Hartemink bedanken voor zijn inzet 
en betrokkenheid bij het onderzoek. Ralf, samen hebben we heel wat creatieve oplossingen bedacht 
voor het verkrijgen van "verse" monsters. Hermien Tolboom wil ik bedanken voor haar bijdrage aan 
de Platos-proef. 
Ik heb grote waardering voor de ondersteuning van mijn voedingsproeven door een 
professioneel team van dietisten. Tijdens het Platos-onderzoek heb ik veel geleerd van hun 
werkwijze. Saskia Meyboom was toen de drijvende kracht: Sas, bedankt voor de gezelligheid en 
sorry voor de stress die de proef (met name de moeizame werving) jou soms bezorgde. Els 
Siebelink en Karin Roosemalen: jullie waren de zonnetjes in de keuken, dat heeft ons veel 
complimenten opgeleverd! 
Ik wil Jan Salemans en Martijn Katan bedanken voor hun bijdrage aan de pouch-proef. 
Martijn, je bent een goede schrijfcoach, ik heb veel van je geleerd. Ik wil Carel Bakx, Eloy van de 
Lisdonk en alle artsen en assistenten van de participerende huisartspraktijken bedanken voor hun 
bijdrage aan de diaboligo-proef. 
In het totaal deden er meer dan 100 vrijwilligers mee aan mijn onderzoeken. Allemaal 
gemotiveerde mensen die in naam van de wetenschap vieze drankjes dronken, ontlasting en urine 
verzamelden, bloed afstonden, dagboekjes bijhielden en zich aan de strenge regels hielden. Zonder 
deze vrijwilligers had ik het onderzoek niet kunnen doen. Ik wil jullie allemaal heel hartelijk 
bedanken voor jullie bijdrage aan dit proefschrift. 
Vanaf de eerste dag van mijn aanstelling zat ik in "room o-o-three". Dat was een prima plekje, met 
geweldige kamergenoten. Marjolein; samen bedachten we 003-ontspanningsmogelijkheden; 
punniken, ringwerpen, lezen in "Emoties", ranspotten, rood-witjes eten en veel koffie drinken! Was 
gezellig! "Pappa" Sunil; thank you for still being a far-a-way friend, love "busy bee". Caroline; 
bedankt voor je betrokkenheid bij mijn proefschrift. Je bent een lieve vriendin, fijn dat je mijn 
paranimf wilt zijn. Karin, met jou heb ik veel gepraat over de belangrijke dingen in het leven. Via 
"motivatie" en "wat vaart erin" komen we er wel! Bedankt voor je steun in barre tijden! Rianne, jij 
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sluit het rijtje. Het was een hele ervaring ineens een kopje looizuur-arme thee te drinken op een 
kamer waar zelfs de planten koffie leuten. Ondanks al die eng "gezonde" voedingsgewoonten was je 
een lieve kamergenoot! 
Daarnaast wil ik alle andere vakgroepsgenoten bedanken voor hun steun. Op het secretariaat 
van de vakgroep kon ik terecht voor moederlijk advies, roddels en andere belangrijke zaken. 
Mama's Riet, Marie, Riekie en Ans: bedankt! Jan Burema, bedankt voor je statistische adviezen, 
Ben Scholte en Dirk Jochems voor IT-ondersteuning en mensen van de technologische hal voor 
jullie hulp met droogijsboxen, vrieskisten en maalmachines. Een aantal lieve AlO-maatjes wil ik 
speciaal noemen. Redge, Gerda, Toine, Peter en andere Reutum-gangers: jullie zijn echte vrienden 
geworden. Bedankt! Marie-Louise: bedankt voor je vriendschap en voor de stimulerende discussies 
over ons vakgebied. Fijn dat ik altijd bij je terecht kon! Ook Rob, Annet, Saskia, Ingeborg, Nicole, 
Nynke en alle anderen, bedankt voor de gezelligheid. 
Mijn collega's bij RCD wil ik bedanken voor de goede werksfeer en voor de mogelijkheid 
die ik kreeg om op 50% basis te starten. 
Voor de nodige afleiding zorgden mijn (schoon)familie en vrienden. Bedankt voor jullie oprechte 
interesse in mijn werk en we gaan rustig door met wandel-weekendjes, toneelspelen, 
stoombadderen, kano-varen 
Dit proefschrift draag ik op aan mijn ouders. Papa en mama, jullie staan aan de basis van 
mijn carriere! Jullie geven mij zelfvertrouwen en helpen nog altijd (vanaf de zijlijn) bij belangrijke 
beslissingen in mijn leven. Bedankt voor jullie stimulerende belangstelling in mijn werk en leven! 
Floor, lief zusje, jij bent er gewoon altijd: van stand-in keukenhulp bij de Platos-proef tot mijn 
microsoft-held bij het lay-outen. Hopelijk blijf je ons steeds verrassen met doordeweekse bezoekjes. 
Lieve Anno, fijn dat je bij me was en me kon steunen bij mijn onderzoek. Jij hebt de gave om mij 
rustig en vrolijk te maken en dat kwam soms goed van pas. "Fietspad, dus niet brommen". En dan 
nu op naar ons volgende project! 
fWfci nc 
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